###begin article-title 0
Endothelial-Rac1 Is Not Required for Tumor Angiogenesis unless alphavbeta3-Integrin Is Absent
###end article-title 0
###begin p 1
Conceived and designed the experiments: GD SDR KHD. Performed the experiments: GD SDR MG LER GJT GS MF VLJT GM. Analyzed the data: GD SDR KHD. Contributed reagents/materials/analysis tools: GE. Wrote the paper: GD SDR KHD.
###end p 1
###begin p 2
Current address: Biomedicum Helsinki, University of Helsinki, Helsinki, Finland
###end p 2
###begin p 3
###xml 116 124 116 124 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 182 189 182 189 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 500 507 500 507 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 511 518 511 518 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ex vivo</italic>
###xml 702 707 702 704 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#946;3</bold>
###xml 824 829 821 823 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#946;3</bold>
###xml 914 919 904 906 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#946;3</bold>
###xml 340 344 <span type="species:ncbi:10090">mice</span>
###xml 835 839 <span type="species:ncbi:10090">mice</span>
Endothelial cell migration is an essential aspect of tumor angiogenesis. Rac1 activity is needed for cell migration in vitro implying a requirement for this molecule in angiogenesis in vivo. However, a precise role for Rac1 in tumor angiogenesis has never been addressed. Here we show that depletion of endothelial Rac1 expression in adult mice, unexpectedly, has no effect on tumor growth or tumor angiogenesis. In addition, repression of Rac1 expression does not inhibit VEGF-mediated angiogenesis in vivo or ex vivo, nor does it affect chemotactic migratory responses to VEGF in 3-dimensions. In contrast, the requirement for Rac1 in tumor growth and angiogenesis becomes important when endothelial beta3-integrin levels are reduced or absent: the enhanced tumor growth, tumor angiogenesis and VEGF-mediated responses in beta3-null mice are all Rac1-dependent. These data indicate that in the presence of alphavbeta3-integrin Rac1 is not required for tumor angiogenesis.
###end p 3
###begin title 4
Introduction
###end title 4
###begin p 5
###xml 309 312 309 312 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009766-Carmeliet1">[1]</xref>
###xml 587 590 587 590 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009766-Silva1">[2]</xref>
###xml 667 672 663 665 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#946;3</bold>
###xml 730 735 719 721 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#946;3</bold>
###xml 810 813 796 799 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009766-Silva1">[2]</xref>
###xml 828 833 810 812 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#946;3</bold>
###xml 1027 1030 1006 1009 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009766-Eskens1">[3]</xref>
###xml 1032 1035 1011 1014 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009766-Friess1">[4]</xref>
###xml 1037 1040 1016 1019 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009766-Gutheil1">[5]</xref>
###xml 1042 1045 1021 1024 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009766-Hariharan1">[6]</xref>
###xml 1047 1050 1026 1029 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009766-Nabors1">[7]</xref>
###xml 1255 1258 1234 1237 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009766-Kerbel1">[8]</xref>
###xml 1260 1263 1239 1242 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009766-Stupp1">[9]</xref>
###xml 1265 1269 1244 1248 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009766-Tucker1">[10]</xref>
###xml 1271 1275 1250 1254 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009766-Ellis1">[11]</xref>
###xml 1343 1348 1322 1324 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#946;3</bold>
###xml 1485 1489 1461 1465 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009766-Reynolds1">[12]</xref>
###xml 1552 1557 1528 1530 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#946;3</bold>
###xml 1617 1621 1590 1594 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009766-Mahabeleshwar1">[13]</xref>
###xml 1222 1229 <span type="species:ncbi:9606">patient</span>
Tumor growth and metastasis are both dependent on the development of a tumor vasculature in a process termed angiogenesis. This process involves changes in the migration and proliferation of endothelial cells to form capillaries which invade into the growing tumor mass to supply it with nutrients and oxygen [1]. The list of molecular co-ordinators of angiogenesis is vast and includes some members of the family of extracellular adhesion molecules, integrins, and several growth factors and their receptors such as vascular endothelial growth factor (VEGF) and VEGF-receptor2 (VEGFR2) [2]. Blood vascular endothelial cells express several integrins including alphavbeta3, a predominant vitronectin receptor. Inhibitors of alphavbeta3 have been developed as anti-angiogenic agents for the treatment of cancer [2]. Indeed alphavbeta3- and VEGF-inhibitors, used in combination with chemotherapy, are both in Phase III clinical trials, the former for the treatment of glioblastoma and the latter especially for colorectal cancer [3], [4], [5], [6], [7]. However, neither anti-integrin nor anti-VEGF treatments are effective enough at blocking angiogenesis to completely halt cancer progression and, at best, can extend mean patient survival by a few months [8], [9], [10], [11]. In contrast to the inhibition studies, global genetic ablation of beta3-integrin results in viable, fertile animals which display enhanced pathological angiogenesis due in part to the up-regulation of VEGFR2 [12], whereas in a transgenic model, where the cytoplasmic tail of beta3-integrin is mutated, pathological angiogenesis is impaired [13]. Taken together these data demonstrate that the molecular mechanisms by which these molecules regulate angiogenesis are complex and in need of further investigation.
###end p 5
###begin p 6
###xml 47 51 47 48 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#946;</bold>
###xml 152 156 149 150 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#946;</bold>
###xml 252 256 246 247 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#946;</bold>
###xml 324 328 315 316 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#946;</bold>
###xml 486 490 474 478 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009766-LeGat1">[14]</xref>
###xml 496 500 484 485 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#946;</bold>
###xml 574 578 559 563 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009766-Hamano1">[15]</xref>
###xml 644 648 629 630 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#946;</bold>
###xml 659 663 641 645 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009766-Mechtersheimer1">[16]</xref>
###xml 748 752 730 731 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#946;</bold>
###xml 763 767 742 746 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009766-Sato1">[17]</xref>
###xml 769 773 748 752 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009766-Sato2">[18]</xref>
###xml 857 861 836 837 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#946;</bold>
###xml 911 915 887 891 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009766-Oxboel1">[19]</xref>
###xml 952 956 928 929 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#946;</bold>
###xml 1044 1045 1017 1018 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 1110 1114 1083 1084 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#946;</bold>
###xml 1125 1129 1095 1099 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009766-Hamano1">[15]</xref>
###xml 1194 1198 1164 1165 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#946;</bold>
###xml 1295 1299 1262 1263 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#946;</bold>
###xml 1401 1405 1361 1362 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#946;</bold>
###xml 1467 1471 1424 1425 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#946;</bold>
###xml 1619 1623 1573 1574 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#946;</bold>
###xml 195 203 <span type="species:ncbi:9606">patients</span>
###xml 377 382 <span type="species:ncbi:10090">mouse</span>
There are several examples where the levels of beta3-integrin have been reported to be undetectable in developing blood vessels. Apart from the lack of beta3-integrin in Glanzmann thromabastenic patients, there are several physiological examples where beta3 levels are low or undetectable: (1) during embryonic development, beta3-integrin expression is barely detectable until mouse embryonic day E15.5 onwards, before which, most developmental angiogenesis is already well established [14]; (2) beta3-integrin expression is not observed in the vasculature of healing liver [15]; (3) the vasculature of angiosarcomas has undetectable levels of beta3-integrin [16]; (4) the vasculature of lung metastases originated from colorectal cancer also lack beta3-integrin [17], [18]; (5) the blood vessels in neuroendocrine tumors also show no significant change in beta3-integrin levels between normal and tumor tissue [19]; (6) in Lewis cell lung carcinomas, beta3-integrin expression is absent until the tumors reach a relatively large size of 500 mm3 or more suggesting that the initial stages of angiogenesis lack beta3-integrin [15]. Taken together, these types of data suggest that screening for beta3-integrin levels, will be important in better detecting which tumor types will be responsive to beta3-specific anti-angiogenic therapy. Indeed the lack of an anti-tumor effect of many of the anti-alphavbeta3-inhibitors, except for in glioblastma, suggest that perhaps beta3-integrin in the vasculature of some tumors is not significantly high or functional. Thus it is of importance to understand the molecular basis of beta3-integrin low/deficient angiogenesis.
###end p 6
###begin p 7
###xml 394 398 394 398 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009766-Jaffe1">[20]</xref>
###xml 584 592 584 592 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 592 596 592 596 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009766-Bryan1">[21]</xref>
###xml 598 602 598 602 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009766-Merajver1">[22]</xref>
###xml 737 741 737 741 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009766-Tzima1">[23]</xref>
###xml 818 825 818 825 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 1096 1100 1096 1100 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009766-Sawada1">[24]</xref>
###xml 1354 1358 1354 1358 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009766-Tan1">[25]</xref>
###xml 1527 1534 1527 1534 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 879 883 <span type="species:ncbi:10090">mice</span>
###xml 1054 1058 <span type="species:ncbi:10090">mice</span>
###xml 1141 1145 <span type="species:ncbi:10090">mice</span>
Downstream signalling pathways of both integrins and growth factor receptors involve RhoA, Cdc42 and Rac1, all members of the family of Rho GTPases. RhoA, Cdc42 and Rac1 can be activated when GTP-bound, and inactivated, when GDP-bound. The activation of RhoA has been reported to be involved in the development of actin stress fibres, Cdc42 in filopodia formation and Rac1 in membrane-ruffling [20]. Rac1 has been shown to be required for the migration of cells, including endothelial cells, and also it appears to play a role in vascular tube formation and lumen formation, at least in vitro[21], [22]. Its involvement in the function of endothelial cells has also been illustrated by the activation of Rac1 under flow and shear stress [23]. Recently, some studies have suggested a role for Rac1 in endothelial cells in vivo. For example, haploinsufficiency of Rac1 in Tie2-Cre mice results in the poor regulation of blood pressure, vasodilation and impaired hind limb ischemia-induced neovascularization, suggesting that a 50% loss of Rac1 in Tie2-Cre mice is sufficient to affect this process [24]. In addition, Rac1-deletion in Tie2-Cre mice has implied a role for Rac1 in developmental vasculogenesis, due, possibly, to its deletion both in Tie2-positive endothelial cells and in approximately 80% of hematopoetic cells which are also Tie2-positive [25]. However, since these embryos die at E9.5, before developmental angiogenesis can proceed fully, the precise effect of endothelial-Rac1-deficiency in tumor angiogenesis in vivo is unknown.
###end p 7
###begin p 8
###xml 198 203 198 200 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#946;3</bold>
###xml 482 489 479 486 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 529 537 526 534 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 165 169 <span type="species:ncbi:10090">mice</span>
Here we show that, surprisingly, the inducible-deletion of Rac1 in adult endothelial cells does not affect tumor angiogenesis or VEGF-mediated angiogenesis in adult mice. However, in the absence of beta3-integrin, the dependency of these processes on Rac1 becomes apparent. Our data indicate that Rac1, in adult endothelial cells, is not normally required for the migration and capillary formation necessary in adult neovascularization in vivo and that the role for this Rho GTPase in vivo may well be different to its functions in vitro.
###end p 8
###begin title 9
Results
###end title 9
###begin title 10
###xml 69 73 <span type="species:ncbi:10090">mice</span>
Tumor growth and tumor angiogenesis in beta3-null, but not wild-type mice, are dependent on adult endothelial Rac1 expression
###end title 10
###begin p 11
###xml 178 182 178 182 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009766-Lamalice1">[26]</xref>
###xml 330 335 330 332 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#946;3</bold>
###xml 440 445 437 439 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#946;3</bold>
###xml 460 465 454 456 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#946;3</bold>
###xml 555 567 546 558 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 1A, B</bold>
###xml 555 567 546 558 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0009766-g001"><bold>Figure 1A, B</bold></xref>
###xml 626 631 617 619 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#946;3</bold>
###xml 642 646 630 634 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009766-Reynolds1">[12]</xref>
###xml 753 758 741 743 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#946;3</bold>
###xml 434 439 <span type="species:ncbi:9606">human</span>
###xml 637 641 <span type="species:ncbi:10090">mice</span>
###xml 764 768 <span type="species:ncbi:10090">mice</span>
Endothelial cell migration is a critical feature of tumor angiogenesis and is thought to involve both changes in integrin expression and the activity of Rho GTPases such as Rac1 [26]. However, a precise role for Rac1 in tumor angiogenesis has never been addressed. We provide evidence that Rac1 activity (Rac1-GTP) is elevated in beta3-integrin knockout endothelial cells without affecting total Rac1 levels, and that transduction of human beta3-integrin into beta3-null endothelial cells is sufficient to reduce Rac1-GTP levels back to wild-type levels (Figure 1A, B). Given the enhanced pathological angiogenic responses in beta3-null mice [12] we asked whether endothelial Rac1 was differentially required in tumor angiogenesis in adult wild-type or beta3-null mice.
###end p 11
###begin title 12
Increased active levels of Rac1 in beta3-integrin-deficient endothelial cells.
###end title 12
###begin p 13
###xml 0 2 0 2 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A.</bold>
###xml 757 759 745 747 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B.</bold>
###xml 241 246 <span type="species:ncbi:9606">human</span>
A. Active levels of Rac1 were examined by GST-PAK pull-downs. Western blot analysis of active Rac1 bound to GST-PAK (Rac1-GTP) and total Rac1 from wild-type, beta3-integrin null, and beta3-null primary lung endothelial cells transduced with human beta3-integrin (rescue). Immunoblots were quantified by densitometry, and the levels of GTP-bound Rac1 normalised to total Rac1 levels. Active levels of Rac1 were increased approximately 3 fold in beta3-null endothelial cells when compared with wild-type controls (*P<0.01), however, total levels of Rac1 were expressed equally in both genotypes. Furthermore, active levels of Rac1 were reduced to wild-type levels in rescue cells (*P<0.01). Results shown are the means + s.e.m of 3-4 independent experiments. B. Flow-cytometric analysis shows that surface levels of beta3-integrin were not detectable in beta3-null (dashed line) cells when compared with wild-types (bold line) endothelial cells (left panel). Rescue cells expressed beta3-integrin (bold line, right panel). Grey peaks represent isotope IgG controls. Bar graph shows means + s.e.m of relative surface beta3-integrin expression in wild-type (white), beta3-null (black) and rescue (grey) endothelial cells compared with negative control (*P<0.001, N = 3 independent experiments).
###end p 13
###begin p 14
###xml 349 356 349 356 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 125 129 <span type="species:ncbi:10090">mice</span>
To investigate whether Rac1-deficiency in endothelial cells affected tumor growth and tumor-associated angiogenesis in adult mice, a lentiviral vector for conditional, Cre-lox regulated, stable RNA interference (RNAi) was employed (pSico-Rac1). This vector allows tissue-specific activation of Rac1 short hairpin RNA (shRNA) in Cre-expressing cells in vivo. As a positive control (for inhibiting angiogenesis), pSico-Flk-1 was employed for the depletion of Flk-1 (VEGFR2). As a negative control pSico-Con, targeting firefly luciferase was also used.
###end p 14
###begin p 15
###xml 46 54 46 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 541 550 541 550 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 2A</bold>
###xml 541 550 541 550 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0009766-g002"><bold>Figure 2A</bold></xref>
###xml 837 846 837 846 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 2B</bold>
###xml 837 846 837 846 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0009766-g002"><bold>Figure 2B</bold></xref>
The efficiency of the system was first tested in vitro. The pSico plasmid contains a GFP-reporter that is excised after Cre-mediated recombination and shRNA expression. Wild-type primary endothelial cells infected with pSico-Rac1 lentiviruses were analyzed for GFP-expression and showed high-efficiency transduction. GFP-positive cells were then isolated by FACS and transfected with a Cre expression-plasmid (pTURBO-Cre). Near complete recombination, with a subsequent loss of GFP expression, was observed for all transduced cells (P<0.01, Figure 2A). Moreover, a significant reduction of both Rac1 and Flk-1 mRNA and protein levels was achieved in pSico-Rac1 or pSico-Flk-1 transduced cells, respectively. As expected, no significant changes in either mRNA or protein levels of Rac1 or Flk-1 were observed in pSico-Con infected cells (Figure 2B).
###end p 15
###begin title 16
Cre-regulated depletion of Rac1.
###end title 16
###begin p 17
###xml 0 2 0 2 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A.</bold>
###xml 367 369 363 365 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B.</bold>
A. Wild-type primary endothelial cells were infected with pSico-Rac1 lentivirus. High-efficiency transduction was achieved as indicated by uniform GFP expression in infected cells (left panel). Cells sorted for GFP positivity and transfected with a Cre-recombinase expression plasmid (pTURBO-Cre) showed a significant loss of GFP (right panel). Scale bar: 10 microm. B. One week after pTURBO-Cre transfection, levels of mRNA, detected by semi-quantitative RT-PCR (upper panels), and protein, detected by Western blotting (lower panels), showed successful Rac1- and Flk-1-depletion in pSico-Rac1 and pSico-Flk-1 infected cells, respectively. Alphactin RT-PCR and Western blotting for Hsc-70 were carried out to ensure equal RNA and protein loading, respectively. Bar graphs represent densitometric readouts of mRNA of relative Actin or Hsc-70 protein levels, respectively. *P<0.01. N = 3 independent experiments.
###end p 17
###begin p 18
###xml 69 70 69 70 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 75 80 75 77 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#946;3</bold>
###xml 94 95 91 92 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 333 337 330 334 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009766-Reynolds1">[12]</xref>
###xml 339 343 336 340 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009766-Reynolds2">[27]</xref>
###xml 377 382 374 376 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#946;3</bold>
###xml 396 397 390 391 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 456 457 450 451 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 697 698 691 692 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 745 750 739 741 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#946;3</bold>
###xml 764 765 755 756 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 772 781 763 772 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 3A</bold>
###xml 772 781 763 772 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0009766-g003"><bold>Figure 3A</bold></xref>
###xml 96 100 <span type="species:ncbi:10090">mice</span>
###xml 135 141 <span type="species:ncbi:10090">murine</span>
###xml 398 402 <span type="species:ncbi:10090">mice</span>
###xml 458 462 <span type="species:ncbi:10090">mice</span>
###xml 699 703 <span type="species:ncbi:10090">mice</span>
###xml 766 770 <span type="species:ncbi:10090">mice</span>
To study the effect of pSico-Rac1 on tumor growth, wild-type/Tie1-Cre+ and beta3-null/Tie1-Cre+ mice were injected subcutaneously with murine B16F0 melanoma cells and pSico-Con, pSico-Rac1 or pSico-Flk-1 lentiviral suspensions injected intratumorally on days 5 and 10 after tumor cell inoculation. In line with our previous findings [12], [27], tumor size in pSico-Con treated beta3-null/Tie1-Cre+ mice was greater than similarly treated wild-type/Tie1-Cre+ mice. Results also showed that although pSico-Flk-1 treatment reduced significantly B16F0 melanoma size (P<0.05) in both genotypes, when compared with pSico-Con controls, pSico-Rac1-treatment did not affect tumor size in wild-type/Tie1-Cre+ mice, but significantly reduced tumor size in beta3-null/Tie1-Cre+ mice (Figure 3A).
###end p 18
###begin title 19
###xml 75 79 <span type="species:ncbi:10090">mice</span>
###xml 103 107 <span type="species:ncbi:10090">mice</span>
Endothelial-specific Rac1-depletion does not impair tumor growth wild-type mice but does in beta3-null mice.
###end title 19
###begin p 20
###xml 0 2 0 2 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A.</bold>
###xml 25 26 25 26 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 94 95 94 95 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 118 119 115 116 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 159 160 156 157 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 477 478 474 475 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 629 630 623 624 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 679 680 673 674 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 687 692 681 686 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n.s.d</italic>
###xml 754 756 748 750 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B.</bold>
###xml 918 919 912 913 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 955 956 943 944 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1250 1257 1235 1242 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 1433 1434 1418 1419 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1458 1459 1440 1441 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1527 1534 1509 1516 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 1597 1598 1575 1576 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1602 1603 1580 1581 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 1649 1650 1627 1628 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 1763 1764 1741 1742 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1788 1789 1763 1764 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1850 1851 1822 1823 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1902 1903 1874 1875 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1910 1915 1882 1887 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n.s.d</italic>
###xml 3 9 <span type="species:ncbi:10090">Murine</span>
###xml 120 124 <span type="species:ncbi:10090">mice</span>
###xml 551 555 <span type="species:ncbi:10090">mice</span>
###xml 681 685 <span type="species:ncbi:10090">mice</span>
###xml 957 961 <span type="species:ncbi:10090">mice</span>
###xml 1190 1194 <span type="species:ncbi:10090">mice</span>
###xml 1460 1464 <span type="species:ncbi:10090">mice</span>
###xml 1732 1736 <span type="species:ncbi:10090">mice</span>
###xml 1790 1794 <span type="species:ncbi:10090">mice</span>
###xml 1852 1856 <span type="species:ncbi:10090">mice</span>
###xml 1904 1908 <span type="species:ncbi:10090">mice</span>
A. Murine B16F0 cells (106) were injected subcutaneously into the flanks of wild-type/Tie1-Cre+ or beta3-null/Tie1-Cre+ mice. Lentiviral vector suspensions (106 i.u/ml) of pSico-Con, pSico-Rac1 and pSico-Flk-1 were injected intratumorally on days 5 and 10 after tumor cell injection. Representative macroscopic appearance of 14-day-old B16F0 pSico-Con-, pSico-Rac1- and pSico-Flk-1- treated melanomas in both genotypes. Scale bar: 5 mm. Bar graph shows mean tumor volume per mm3 (+ s.e.m.). Tumor size was reduced significantly in pSico-Flk-1-treated mice of both genotypes (*P<0.05) and in pSico-Rac1 treated beta3-null/Tie1-Cre+ but not in pSico-Rac1-treated wild-type/Tie1-Cre+ mice (n.s.d, no significant differences). N = 4-6 animals per condition. B. Representative merged images of PECAM-1 (red) and GFP (green) -immunostained sections from pSico-Rac1-treated B16F0 tumors grown in wild-type, wild-type/Tie1-Cre+, beta3-null and beta3-null/Tie1-Cre+ mice. PECAM-1-positive staining identified endothelium. GFP-positive staining was observed in tumor cells (concave arrowheads) and in PECAM+ endothelium (arrows) of blood vessels in B16F0 tumors from wild-type and beta3-null control mice, indicating successful pSico-Rac1 lentivirus infection in vivo. Loss of GFP detection in most PECAM-1-positive microvessels (small arrowheads), but not in B16F0 tumor cells, was observed in pSico-treated tumors grown in wild-type/Tie1-Cre+ and beta3-null/Tie1-Cre+ mice, indicating successful endothelial-specific Cre recombination in vivo. Scale bar: 10 microm. Bar graph shows mean numbers of PECAM-1+/GFP- vessels per unit area of tumor section per mm2 (+ s.e.m). Blood vessel density was reduced significantly in pSico-Flk-1-treated mice of both wild-type/Tie1-Cre+ and beta3-null/Tie1-Cre+ mice (*P<0.05) and in pSico-Rac1-treated beta3-null/Tie1-Cre+ mice but not pSico-Rac1-treated wild-type/Tie1-Cre+ mice (n.s.d, no significant differences). N = 4 animals per condition.
###end p 20
###begin p 21
###xml 46 53 46 53 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 160 161 160 161 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 183 184 183 184 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 346 347 346 347 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 519 526 519 526 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 587 588 587 588 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 738 747 738 747 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 3B</bold>
###xml 738 747 738 747 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0009766-g003"><bold>Figure 3B</bold></xref>
###xml 872 873 872 873 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 185 189 <span type="species:ncbi:10090">mice</span>
###xml 348 352 <span type="species:ncbi:10090">mice</span>
###xml 589 593 <span type="species:ncbi:10090">mice</span>
To determine the efficacy of the lentiviruses in vivo, double-immunostaining for PECAM-1 and GFP was performed in sections of tumors grown in wild-type/Tie1-Cre- or wild-type/Tie1-Cre+ mice treated with either pSico-Rac1 or pSico-Flk-1 lentiviruses. Immunostaining for PECAM-1 identified blood vessels under both conditions. In wild-type/Tie1-Cre- mice, GFP expression was detected in both the tumor cells and the majority of endothelial cells lining blood vessels, indicating a high efficiency of lentiviral infection in vivo. In contrast, analysis of tumors grown in wild-type/Tie1-Cre+ mice showed a loss of GFP expression in endothelial cells but not tumor cells, indicating that endothelial-specific Cre-recombination was efficient (Figure 3B). Taken together, these data indicate that, while no biological effect of Rac-1 knockdown was observed in wild-type/Tie1-Cre+, the lentivirus treatment efficiently reduced expression of Rac1 in tumor blood vessels from these animals.
###end p 21
###begin p 22
###xml 145 146 145 146 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 150 151 150 151 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 263 264 263 264 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 269 274 269 271 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#946;3</bold>
###xml 288 289 285 286 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 412 416 409 413 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009766-Reynolds1">[12]</xref>
###xml 418 422 415 419 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009766-Reynolds2">[27]</xref>
###xml 466 471 463 465 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#946;3</bold>
###xml 485 486 479 480 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 562 563 556 557 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 679 680 673 674 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 685 690 679 681 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#946;3</bold>
###xml 704 705 695 696 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 797 798 788 789 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 851 856 842 844 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#946;3</bold>
###xml 870 871 858 859 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 878 887 866 875 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 3B</bold>
###xml 878 887 866 875 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0009766-g003"><bold>Figure 3B</bold></xref>
###xml 290 294 <span type="species:ncbi:10090">mice</span>
###xml 487 491 <span type="species:ncbi:10090">mice</span>
###xml 564 568 <span type="species:ncbi:10090">mice</span>
###xml 706 710 <span type="species:ncbi:10090">mice</span>
###xml 872 876 <span type="species:ncbi:10090">mice</span>
To examine the effect of endothelial Rac1-depletion on tumor angiogenesis, blood vessel density was quantified by counting the numbers of PECAM-1+/GFP- blood vessels per unit area across entire midline tumor sections from size-matched tumors of wild-type/Tie1-Cre+ and beta3-null/Tie1-Cre+ mice treated with either pSico-Con, pSico-Rac1 or pSico-Flk-1 lentiviruses. Once again, concurrent with our previous work [12], [27], blood vessel density in pSico-Con treated beta3-null/Tie1-Cre+ mice was significantly greater than in pSico-Con treated wild-type/Tie1-Cre+ mice. However, although pSico-Flk-1 treatment inhibited significantly tumor angiogenesis in both wild-type/Tie1-Cre+ and beta3-null/Tie1-Cre+ mice (P<0.05), pSico-Rac1-treatment did not affect tumor angiogenesis in wild-type/Tie1-Cre+ but did inhibit tumor angiogenesis significantly in beta3-null/Tie1-Cre+ mice (Figure 3B).
###end p 22
###begin p 23
###xml 142 143 142 143 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 190 195 190 192 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#946;3</bold>
###xml 209 210 206 207 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 144 148 <span type="species:ncbi:10090">mice</span>
###xml 211 215 <span type="species:ncbi:10090">mice</span>
These results indicate that Rac1-depletion in tumor endothelial cells does not affect tumor growth or tumor angiogenesis in wild-type/Tie1-Cre+ mice but does inhibit both these processes in beta3-null/Tie1-Cre+ mice.
###end p 23
###begin p 24
###xml 219 223 219 223 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009766-Walmsley1">[28]</xref>
###xml 387 391 387 391 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009766-Claxton1">[29]</xref>
###xml 1152 1161 1152 1161 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 4A</bold>
###xml 1152 1161 1152 1161 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0009766-g004"><bold>Figure 4A</bold></xref>
###xml 1535 1544 1535 1544 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 4B</bold>
###xml 1535 1544 1535 1544 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0009766-g004"><bold>Figure 4B</bold></xref>
###xml 214 218 <span type="species:ncbi:10090">mice</span>
###xml 255 270 <span type="species:ncbi:10090">transgenic mice</span>
###xml 461 465 <span type="species:ncbi:10090">mice</span>
###xml 695 699 <span type="species:ncbi:10090">mice</span>
###xml 1113 1117 <span type="species:ncbi:10090">mice</span>
###xml 1192 1196 <span type="species:ncbi:10090">mice</span>
Further confirmation of the role of endothelial Rac1 in tumor growth and angiogenesis was accomplished by using a genetic ablation approach that allows conditional Rac1-deletion in an inducible-manner. Rac1-floxed mice [28] were crossed with PDGFB-iCreER transgenic mice (23) (where Cre expression, in adult animals, is restricted primarily to angiogenic/proliferating endothelial cells [29]) to generate tamoxifen-inducible endothelial-specific Rac1-deficient mice (Rac1 flox/flox PDGFB-iCreER). To verify that tamoxifen treatment of Rac1 flox/flox PDGFB-iCreER endothelial cells induced Rac1-deletion, endothelial cells and non-endothelial cells were isolated from Rac1 flox/flox PDGFB-iCreER mice and treated with tamoxifen (OHT) or ethanol (vehicle) in culture. Rac1 protein levels were barely detected in Rac1 flox/flox PDGFB-iCreER tamoxifen-treated endothelial cells when compared with vehicle-alone treated Rac1 flox/flox PDGFB-iCreER or tamoxifen-treated Rac1 flox/flox (PDGFB-iCreER negative) controls. Importantly, tamoxifen treatment of non-endothelial cells isolated from Rac1 flox/flox PDGFB-iCreER mice had no effect on Rac1 expression (Figure 4A). Rac1 flox/flox PDGFB-iCreER mice were injected subcutaneously with B16F0 cells and, one day later, treated with tamoxifen (OHT) or placebo administered by slow-release pellets implanted subcutaneously to induce Cre-activity in PDGFB-positive cells. Deletion of Rac1 in the vascular endothelium did not affect tumor size or tumor angiogenesis when compared with controls (Figure 4B).
###end p 24
###begin title 25
Genetic ablation of Rac1 in endothelial cells does not impair tumor growth or tumor angiogenesis.
###end title 25
###begin p 26
###xml 0 2 0 2 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A.</bold>
###xml 566 568 566 568 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B.</bold>
###xml 815 816 815 816 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 1031 1032 1031 1032 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 1172 1174 1172 1174 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C.</bold>
###xml 1492 1493 1489 1490 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 1505 1506 1502 1503 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1623 1624 1620 1621 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 1637 1638 1634 1635 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 765 769 <span type="species:ncbi:10090">mice</span>
A. Western blot analysis of Rac1 flox/flox PDGFB-iCreER OHT-treated primary endothelial cell extracts showed that Rac1 was barely detectable (lane 3) when compared with Rac1 flox/flox OHT-treated (lane 1) or Rac1 flox/flox PDGFB-iCreER vehicle treated (lane 2) endothelial cell extracts (left panel). Western blots of extracts from non-endothelial cells, treated as described above, showed no differences in Rac1 expression (right panel). Hsc-70 provided loading controls. Bar graphs represent densitometric values relative to Hsc-70. N = 2 independent experiments. B. B16F0 tumor volume and angiogenesis (blood vessel density) from tumors grown in OHT-treated Rac1 flox/flox (1, white), or placebo- (2, grey) or OHT- (3, black) treated Rac1 flox/flox PDGFB-iCreER mice. Left bar graph shows mean tumor volume in mm3 (+ s.e.m) for 10-day-old tumors. No significant differences in tumor size were observed between groups. N = 6-7 animals per group. Right bar graph shows mean number of PECAM-1 positive vessels per tumor area per mm2 (+ s.e.m.) for 10-day-old tumors. No significant differences in microvessel density were observed between groups. N = 4 animals per group. C. B16F0 tumor volume and angiogenesis (blood vessel density) from tumors grown in OHT-treated Rac1 flox/flox PDGFB-iCreER animals. Tumors were injected at days 5 and 10 (after initial inoculation) with pSico-Con (1, white) or pSico- beta3 (2, black) and harvested at day 14. Left bar graph shows mean tumor volume in mm3 (+ s.e.m). P<0.05. N = 5 animals per group. Right bar graph shows mean number of endomucin positive vessels per tumor area per mm2 (+ s.e.m.). P<0.001. N = 5 animals per group.
###end p 26
###begin p 27
###xml 89 96 86 93 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 467 468 458 459 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 535 536 523 524 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 543 552 531 540 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 4C</bold>
###xml 543 552 531 540 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0009766-g004"><bold>Figure 4C</bold></xref>
###xml 692 693 677 678 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 701 710 686 695 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 4C</bold>
###xml 701 710 686 695 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0009766-g004"><bold>Figure 4C</bold></xref>
###xml 845 852 830 837 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
As yet an additional test of the roles played by Rac1 and beta3-integrin in angiogenesis in vivo, Rac1 flox/flox PDGFB-iCreER animals received tamoxifen pellet implants. These animals then were injected subcutaneously with B16F0 cells and subsequently received intra-tumoral injections of pSico-Con (as described above) or a pSico lentivirus directed against beta3-integrin (pSico-beta3). Tumors treated with pSico-Con grew to an expected size of approximately 800 mm3. pSico-beta3 treated tumors, however, were significantly smaller (P<0.05, Figure 4C). Blood vessel counts of endomucin stained tumor sections showed a significant reduction in angiogenesis after treatment with pSico-beta3 (P<0.001, Figure 4C). Taken together, data from Rac1 flox/flox PDGFB-iCreER animals provided a second line of evidence that tumor growth and angiogenesis in vivo does not normally depend on Rac1.
###end p 27
###begin p 28
###xml 94 102 94 102 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 102 106 102 106 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009766-Bryan1">[21]</xref>
###xml 108 112 108 112 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009766-Merajver1">[22]</xref>
###xml 333 337 333 337 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009766-Claxton1">[29]</xref>
###xml 634 642 634 642 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 5</bold>
###xml 634 642 634 642 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0009766-g005"><bold>Figure 5</bold></xref>
###xml 742 749 742 749 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
Already published studies suggest that Rac1 plays a role in vascular tube formation, at least in vitro[21], [22]. As such, the data describe here were somewhat surprising. To further test the effect of Rac1 deletion in another neovascularization assay, the influence of Rac1 deletion was analyzed in the post-natal developing retina [29]. Wild-type PDGFB-iCreER and Rac1 flox/flox PDGFB-iCreER newborn pups were treated daily with tamoxifen by oral gavage and their retinas were examined at P12. No significant differences in central primary plexus, or peripheral primary plexus branch points were observed between the two genotypes (Figure 5). Therefore, deficiency of Rac1 in endothelial cells is not sufficient to alter neovasculatization in vivo, at least when beta3-integrin is present.
###end p 28
###begin title 29
Postanatal retinal vascularization is not affected by endothelial Rac1 deletion.
###end title 29
###begin p 30
Wild-type PDGFB-iCreER and PDGFB-iCreER; Rac1 flox/flox newborn pups were treated daily with tamoxifen and their retinas were examined at P12. The vasculature was visualised by Interleukin beta4 staining (ILB4 - green) and Claudin 5 (red). No obvious differences in vascularization were observed between genotypes. Scale bar: 10 microm upper micrographs; 100 microm lower micrographs.
###end p 30
###begin p 31
###xml 15 22 15 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 219 224 219 221 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#946;3</bold>
###xml 148 152 <span type="species:ncbi:10090">mice</span>
Using multiple in vivo approaches, we demonstrated that endothelial Rac1 is not essential for tumor growth or tumor angiogenesis in adult wild-type mice, but that these processes become Rac1-dependent in the absence of beta3-integrin.
###end p 31
###begin title 32
###xml 65 69 <span type="species:ncbi:10090">mice</span>
###xml 91 95 <span type="species:ncbi:10090">mice</span>
Rac1 is not required for VEGF-mediated angiogenesis in wild-type mice but is in beta3-null mice
###end title 32
###begin p 33
###xml 131 139 131 139 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 237 244 237 244 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 317 318 317 318 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 323 328 323 325 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#946;3</bold>
###xml 342 343 339 340 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 362 369 359 366 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in situ</italic>
###xml 630 635 627 629 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#946;3</bold>
###xml 649 650 643 644 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 729 730 723 724 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 897 898 891 892 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 943 948 937 939 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#946;3</bold>
###xml 962 963 953 954 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1008 1017 999 1008 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 6A</bold>
###xml 1008 1017 999 1008 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0009766-g006"><bold>Figure 6A</bold></xref>
###xml 1144 1149 1135 1137 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#946;3</bold>
###xml 1332 1337 1320 1322 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#946;3</bold>
###xml 1368 1369 1353 1354 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(</bold>
###xml 1369 1378 1354 1363 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 6B</bold>
###xml 1369 1378 1354 1363 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0009766-g006"><bold>Figure 6B</bold></xref>
###xml 1378 1380 1363 1365 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">).</bold>
###xml 1560 1565 1545 1547 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#946;3</bold>
###xml 1576 1583 1558 1565 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 344 348 <span type="species:ncbi:10090">mice</span>
###xml 669 673 <span type="species:ncbi:10090">mice</span>
###xml 899 903 <span type="species:ncbi:10090">mice</span>
###xml 964 968 <span type="species:ncbi:10090">mice</span>
###xml 1155 1159 <span type="species:ncbi:10090">mice</span>
###xml 1231 1235 <span type="species:ncbi:10090">mice</span>
###xml 1363 1367 <span type="species:ncbi:10090">mice</span>
###xml 1518 1522 <span type="species:ncbi:10090">mice</span>
###xml 1571 1575 <span type="species:ncbi:10090">mice</span>
Given that VEGF is a key positive regulator of pathological angiogenesis and that VEGF/VEGFR2 signalling is known to activate Rac1 in vitro, we tested the effect of endothelial-specific Rac1-depletion on VEGF-mediated neovascularization in vivo. Synthetic sponges were implanted subcutaneously into wild-type/Tie1-Cre+ and beta3-null/Tie1-Cre+ mice and injected in situ with 10 ng/ml VEGF-A164 in combination with either pSico-Con, pSico-Rac1 or pSico-Flk-1 lentiviral suspensions. After 15-days, angiogenic responses were assayed histologically. Results showed that, as expected, VEGF-mediated neovascularization was elevated in beta3-null/Tie1-Cre+ pSico-Con treated mice when compared with similarly treated wild-type/Tie1-Cre+ controls. pSico-Flk-1 treatment inhibited significantly VEGF-induced angiogenesis in both genotypes. However, pSico-Rac1 treatment had no effect in wild-type/Tie1-Cre+ mice, but did inhibit neovascularization in beta3-null/Tie1-Cre+ mice when compared with pSico-Con controls (Figure 6A). Additionally, using a second approach, VEGF-induced angiogenesis in scrambled control-siRNA (Con siRNA) injected sponges in beta3-null mice was elevated when compared with Con siRNA treated sponges in wild-type mice, and Rac1-specific-siRNA injection into sponges inhibited significantly angiogenic responses in beta3-null, but not wild-type, mice (Figure 6B). Taken together these data suggest that Rac1 expression in endothelial cells is not essential for VEGF-mediated angiogenesis in wild-type mice but is involved in such responses in beta3-null mice in vivo.
###end p 33
###begin title 34
###xml 85 89 <span type="species:ncbi:10090">mice</span>
###xml 108 112 <span type="species:ncbi:10090">mice</span>
VEGF-mediated angiogenesis is dependent on endothelial-Rac1 expression in beta3-null mice but not wild-type mice.
###end title 34
###begin p 35
###xml 0 2 0 2 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A.</bold>
###xml 85 86 85 86 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 110 111 107 108 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 488 489 478 479 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 541 542 531 532 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 549 554 539 544 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n.s.d</italic>
###xml 610 612 600 602 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B.</bold>
###xml 859 860 849 850 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 1034 1039 1024 1029 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n.s.d</italic>
###xml 1098 1100 1088 1090 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C.</bold>
###xml 1586 1588 1569 1571 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D.</bold>
###xml 1588 1595 1571 1578 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ex vivo</italic>
###xml 2253 2258 2230 2235 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n.s.d</italic>
###xml 112 116 <span type="species:ncbi:10090">mice</span>
###xml 409 413 <span type="species:ncbi:10090">mice</span>
###xml 490 494 <span type="species:ncbi:10090">mice</span>
###xml 543 547 <span type="species:ncbi:10090">mice</span>
###xml 659 663 <span type="species:ncbi:10090">mice</span>
###xml 1596 1601 <span type="species:ncbi:10090">mouse</span>
###xml 1735 1740 <span type="species:ncbi:10090">mouse</span>
A. Representative images of 14-day-old VEGF-impregnated sponges in wild-type/Tie1-Cre+ and beta3-null/Tie1-Cre+ mice after treatment with pSico-Con, pSico-Rac1 and pSico-Flk-1. Endomucin-positive staining (blue) identified microvessels. Scale bar: 50 microm. Bar graph represents mean number of microvessels per area of sponge (+ s.e.m.). Blood vessel density was reduced significantly in pSico-Flk-1-treated mice of both genotypes (*P<0.05), and in pSico-Rac1-treated beta3-null/Tie1-Cre+ mice, but not pSico-Rac1-treated wild-type/Tie1-Cre+ mice (n.s.d, no significant differences). N = 6 sponges per group. B. Subcutaneous sponges implanted into wild-type mice were injected with either PBS or VEGF in the presence (Rac1 siRNA) or absence (Con siRNA) of Rac1-specific siRNA. Bar graph shows mean number of laminin-positive vessels per area of sponge per mm2 (+ s.e.m). Blood vessel density was increased significantly in VEGF alone-treated (*P<0.01) when compared with PBS controls. Rac1 siRNA-treatment had no significant effect (n.s.d, no significant differences). N = 6-10 sponges per group. C. Semi-quantitative RT-PCR (left) and Western blot (right) analyzes from wild-type and beta3-null aortic explants transfected with either Con or Rac1 specific-siRNA. Rac1 siRNA reduced significantly the expression of both Rac1 mRNA (*P<0.01) and protein (*P<0.001) levels. RT-PCR for Alphactin and Western blotting for Hsc-70 provided mRNA and protein loading controls, respectively. Bar graphs represent mean Rac1 mRNA and Rac1 protein levels (+ s.e.m.). N = 3 independent experiments. D.Ex vivo mouse aortic ring assays. Representative high-power light micrographs of VEGF-mediated microvessel sprouting from wild-type and beta3-null mouse aortic rings treated with Con or Rac1-specific siRNA and Con siRNA plus DC101. Bar graphs represent quantification of microvessel numbers from 5-day-old VEGF-stimulated aortic ring cultures transfected with Mock, Con or Rac1 siRNA in the presence or absence of DC101. Sprouting angiogenesis was reduced significantly after DC101 treatment of aortas and in Rac1-specific siRNA transfected beta3-null, but not wild-type, aortas. Bar graph represents mean number microvessel sprouts/aortic ring (+ s.e.m.).*P<0.01; n.s.d, no significant differences. N = 3-5 independent experiments.
###end p 35
###begin p 36
###xml 104 111 104 111 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ex vivo</italic>
###xml 173 178 173 175 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#946;3</bold>
###xml 412 421 409 418 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 6C</bold>
###xml 412 421 409 418 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0009766-g006"><bold>Figure 6C</bold></xref>
###xml 551 555 548 552 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009766-Reynolds2">[27]</xref>
###xml 746 751 743 745 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#946;3</bold>
###xml 765 774 759 768 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 6D</bold>
###xml 765 774 759 768 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0009766-g006"><bold>Figure 6D</bold></xref>
###xml 919 928 913 922 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 6D</bold>
###xml 919 928 913 922 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0009766-g006"><bold>Figure 6D</bold></xref>
###xml 184 188 <span type="species:ncbi:10090">mice</span>
Further analysis of the role of Rac1 in VEGF-induced neovascularization responses was carried out using ex vivo aortic ring assays. Thoracic aortic rings from wild-type and beta3-null mice were transfected with either a scrambled control (Con) or Rac1-specific siRNA. Rac1 mRNA and protein levels were reduced in aortic rings from both genotypes by approximately 85% after transfection with Rac1-specific siRNA (Figure 6C). These rings were embedded in Matrigel in the presence of VEGF alone or VEGF plus DC101, an antibody that blocks Flk-1 activity [27]. Quantitation of microvessel outgrowth showed that Rac1-depletion did not alter wild-type microvessel sprouting, but inhibited significantly the enhanced numbers of microvessel sprouts from beta3-null aortas (Figure 6D). In addition, DC101 treatment significantly affected this process in Con- and Rac1-siRNA transfected aortic rings from both genotypes (P<0.01, Figure 6D).
###end p 36
###begin title 37
Rac1-depletion does not affect the levels or activity of other tested Rho GTPases in either wild-type or beta3-null endothelial cells
###end title 37
###begin p 38
###xml 112 117 112 114 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#946;3</bold>
###xml 362 371 356 365 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 7A</bold>
###xml 362 371 356 365 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0009766-g007"><bold>Figure 7A</bold></xref>
###xml 396 405 390 399 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 7B</bold>
###xml 396 405 390 399 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0009766-g007"><bold>Figure 7B</bold></xref>
###xml 432 441 426 435 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 1A</bold>
###xml 432 441 426 435 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0009766-g001"><bold>Figure 1A</bold></xref>
###xml 762 771 753 762 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 7B</bold>
###xml 762 771 753 762 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0009766-g007"><bold>Figure 7B</bold></xref>
###xml 975 980 966 968 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#946;3</bold>
###xml 317 321 <span type="species:ncbi:10090">mice</span>
To begin to understand the mechanisms responsible for the biological effects of Rac1-depletion in wild-type and beta3-null endothelial cells, we examined first the levels and activity of Rac2, Rac3, Cdc42 and Rho. Rac1-specific siRNA treatment of microvascular endothelial cells isolated from wild-type or beta3-null mice reduced significantly Rac1 mRNA levels (Figure 7A), total protein levels (Figure 7B), and active Rac1 levels (Figure 1A). In contrast, transfection of endothelial cells using Con siRNA had no effect on Rac1 expression in either genotype. Importantly, no compensation by expression or activity of other tested Rho-related GTPases (Rac2, Rac3, Cdc42 and RhoA) were observed in either wild-type- or beta3-null-Rac1-depleted endothelial cells (Figure 7B). These results suggest that the lack of an inhibitory response to Rac1 loss in wild-type endothelial cells is not due to compensation by either Rac2, Rac3, Cdc42 or RhoA. In addition, the dependency of beta3-null endothelial cells on Rac1 is not due to any intrinsic change in these Rho GTPases.
###end p 38
###begin title 39
Rac1-depletion in endothelial cells does not affect the expression and activity of other Rho-related GTPases.
###end title 39
###begin p 40
###xml 0 2 0 2 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A.</bold>
###xml 679 681 676 678 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B.</bold>
A. Analysis of mRNA expression of Rac isoforms by RT-PCR. RNA was extracted from wild-type and beta3-null endothelial cells transfected with Con or Rac1 siRNA. As expected, mRNA expression of Rac1 was significantly reduced in Rac1-depleted cells of both genotypes (*P<0.001). Rac2 and Rac3 isoforms were not detected in either Con- or Rac1-siRNA transfected endothelial cells. Extracts of lung (lu), spleen (sp) and brain (br) act as positive controls for Rac1, Rac2 and Rac3, respectively. Actin mRNA provided the internal control. L: ladder. Bar graphs represent relative mRNA levels of Rac1 after Mock- (white), Con- (grey) and Rac1-siRNA (black) treatment in both genotypes. B. Western blot analyses show that Rac1 expression, as expected, was significantly reduced in Rac1-depleted cells of both genotypes (*P<0.01). In contrast, Cdc42 and RhoA protein expression was not significantly affected in endothelial cells after Rac1-siRNA in both genotypes. In addition, for both wild-type and beta3-null endothelial cells active levels of Rac1, Cdc42 and RhoA were examined using GST-PAK pull-down (Rac1 and Cdc42) and G-LISA(R) (RhoA) assays on Mock (white), Con- (grey) and Rac1-siRNA (black) transfected cells. Bars graphs show mean relative protein (top) and active (bottom) levels (+ s.e.m.) of Rac1, Cdc42, and RhoA in Mock (white), Con- (grey) and Rac1-siRNA (black) treated wild-type and beta3-null cells. N = 3 independent experiments.
###end p 40
###begin title 41
Rac1 is not essential for VEGF-mediated endothelial cell proliferation, scratch closure or tube formation in 2-dimensions
###end title 41
###begin p 42
###xml 120 128 120 128 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 183 188 183 185 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#946;3</bold>
Given that Rac1 has been implicated in regulating positively cell migration, proliferation and tube formation, at least in vitro, we decided to examine also whether Rac1-depletion in beta3-null endothelial cells affects these processes.
###end p 42
###begin p 43
###xml 114 119 114 116 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#946;3</bold>
###xml 348 353 345 347 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#946;3</bold>
###xml 378 387 372 381 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 8A</bold>
###xml 378 387 372 381 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0009766-g008"><bold>Figure 8A</bold></xref>
###xml 565 574 559 568 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 8B</bold>
###xml 565 574 559 568 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0009766-g008"><bold>Figure 8B</bold></xref>
###xml 680 685 674 676 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#946;3</bold>
###xml 809 818 800 809 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 8C</bold>
###xml 809 818 800 809 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0009766-g008"><bold>Figure 8C</bold></xref>
###xml 840 849 831 840 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 8D</bold>
###xml 840 849 831 840 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0009766-g008"><bold>Figure 8D</bold></xref>
###xml 932 941 923 932 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 8D</bold>
###xml 932 941 923 932 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0009766-g008"><bold>Figure 8D</bold></xref>
###xml 1221 1225 1212 1216 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009766-Sahai1">[30]</xref>
###xml 1227 1231 1218 1222 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009766-Sahai2">[31]</xref>
###xml 1246 1253 1237 1244 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 1601 1606 1592 1594 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#946;3</bold>
###xml 1799 1804 1787 1789 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#946;3</bold>
###xml 1825 1834 1810 1819 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 8E</bold>
###xml 1825 1834 1810 1819 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0009766-g008"><bold>Figure 8E</bold></xref>
Analysis of endothelial cell growth by seeding equal numbers of Mock, Con- or Rac1-siRNA transfected wild-type or beta3-null endothelial cells and counting the total number of cells per condition between 0 and 3 days showed no significant differences between Rac1-depleted and control cells in either genotype despite the increased growth rates of beta3-null endothelial cells (Figure 8A). In addition, Trypan blue exclusion showed that the percentage of cells that were viable did not change after Rac1-depletion between 1-3 days after seeding in either genotype (Figure 8B). These data suggest that Rac1-knockdown does not inhibit the proliferation or viability of wild-type or beta3-null endothelial cells in culture. In contrast, Rac1-depletion inhibited VEGF-mediated 2-dimensional (2D) scratch closure (Figure 8C) and cord formation (Figure 8D) when compared with Mock and Con siRNA controls without affecting cell viability (Figure 8D). These results confirm the reported role of Rac1 in promoting VEGF-mediated endothelial cell migration and cord formation conducted in standard 2D tissue culture conditions. However, given that the requirement for Rac1 in 3-dimensional (3D) versus 2D migration may be different [30], [31], and that our in vivo data did not show a requirement for Rac1 in wild-type angiogenesis, the effect of Rac1-depletion in endothelial cell migration was examined further in a 3D-modified Boyden chamber assay. Importantly, knockdown of Rac1 had no effect on VEGF-induced 3D chemotactic migration of wild-type endothelial cells, but did inhibit this mode of migration in beta3-null endothelial cells. As controls wild-type endothelial cells transfected with Con siRNA and treated with DC101 showed baseline migration and this was further inhibited in similarly treated beta3-null cells (P<0.05, Figure 8E). These results suggest that the role of Rac1 in 3D and 2D is different.
###end p 43
###begin title 44
Effect of Rac1-depletion in wild-type and beta3-null cells in 2D versus 3D.
###end title 44
###begin p 45
###xml 0 2 0 2 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A.</bold>
###xml 455 457 410 412 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B.</bold>
###xml 697 699 652 654 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C.</bold>
###xml 1333 1335 1279 1281 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D.</bold>
###xml 2080 2082 2023 2025 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E.</bold>
###xml 2082 2090 2025 2033 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In vitro</italic>
###xml 2716 2721 2656 2661 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n.s.d</italic>
A. Endothelial cell growth over 3 days was assessed by counting the total number of Mock, Con- or Rac1-siRNA transfected wild-type and beta3-null endothelial cells. Although beta3-null cells grew faster than wild-type, Rac1-depletion did not affect cell growth in either genotype. Symbols (*, Mock; blacksquare, square, filled, Con-; and black triangle, Rac1-siRNA) values given represent mean total cell numbers (+ s.e.m) from 3 independent experiments. B. Trypan blue exclusion, used to assess cell viability, shows that Rac1 knockdown has no effect on endothelial cell viability in either genotype. Bar graph represents mean percentage of viable cells (+ s.e.m) from 3 independent experiments. C. Wild-type and beta3-null endothelial cell migration in response to VEGF was assessed in scratch wound healing assays. Representative photomicrographs (20 x magnification) of scratches at 0 hr and after 8 hr of migration after VEGF (25 ng/ml) stimulation. Bar graphs represent the mean percentage migration relative to 0 hours (+ s.e.m.), from 3 independent experiments, displayed by Mock (white), Con- (grey) and Rac1-siRNA (black) transfected wild-type and beta3-null endothelial cells. Under 2D conditions, Rac1-depletion inhibited VEGF-induced migration of both wild-type and beta3-null endothelial cell cells to baseline levels. D. VEGF-stimulated endothelial cell tube formation was assessed in 2D Matrigel cultures. Representative phase contrast micrographs (20 x magnification) showing cord structures (arrows) that formed 8 hr after seeding of Con- or Rac1-siRNA transfected cells on 2D Matrigel. Bar graphs represent mean numbers of branch points per field (+ s.e.m.) from 3 independent experiments. Rac1-depletion inhibited significantly VEGF-mediated tube formation by both wild-type and beta3-null endothelial cells (*P<0.0001). Trypan blue exclusion assays demonstrated that the percentage of cell death of cells isolated from the cord-formation experiment did not change. Bar graph represents mean percentage of cell death (+ s.e.m.) from 3 independent experiments. E.In vitro VEGF-mediated endothelial cell migration was assessed in a modified 3D Boyden chamber assay. Quantification of VEGF-mediated migration of Mock, Con- or Rac1-siRNA transfected wild-type (left) and beta3-null (right) endothelial cells in the presence or the absence of DC101. Bar graphs represent mean percentage migration relative to Mock treated cells in the absence of VEGF (+ s.d). VEGF-mediated migration was significantly reduced in Con siRNA DC101 treated endothelial cells, confirming the requirement of Flk-1 in VEGF-induced migration and provides a control (*P<0.05) siRNA targeting of Rac1 did not affect wild-type (n.s.d), but did inhibit beta3-null, endothelial cell migration in 3D conditions (*P<0.01). N = 3-5 independent experiments.
###end p 45
###begin title 46
Rac1 depletion does not affect VEGF-receptor2 expression
###end title 46
###begin p 47
###xml 48 53 48 50 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#946;3</bold>
###xml 139 143 136 140 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009766-Reynolds1">[12]</xref>
###xml 145 149 142 146 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009766-Reynolds2">[27]</xref>
###xml 235 240 232 234 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#946;3</bold>
###xml 649 658 637 646 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 9A</bold>
###xml 649 658 637 646 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0009766-g009"><bold>Figure 9A</bold></xref>
Since we have shown previously that the loss of beta3-integrin can elevate VEGF-mediated responses, VEGFR2/Flk-1 levels and Flk-1 activity [12], [27] we sought to determine the effect of Rac1-depletion on Flk-1 levels in wild-type and beta3-null endothelial cells. Expression of Flk-1 was analyzed in primary wild-type and beta3-null endothelial cells after transfection with either scrambled-control or Rac1-specific siRNA. Western blot analysis recapitulated our previous work showing that beta3-null endothelial cells express higher levels of Flk-1 than wild-type controls. However, Rac1-depletion did not affect Flk-1 levels in either genotype (Figure 9A). This suggested that the elevated Rac1 activity that occurs in beta3-null endothelial cells is downstream of changes in VEGFR2.
###end p 47
###begin title 48
Endothelial Rac1-depletion does not affect the expression of Flk-1.
###end title 48
###begin p 49
###xml 0 2 0 2 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A.</bold>
###xml 345 350 339 344 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n.s.d</italic>
###xml 499 501 493 495 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B.</bold>
A. Western blot analysis of Flk-1 expression levels in primary wild-type and beta3-null endothelial cells transfected with scrambled (Con siRNA) or Rac1 (Rac1 siRNA) siRNAs. Although Flk-1 expression was increased significantly in beta3-null endothelial cells when compared with wild-types (*P<0.01), Rac1-depletion did not affect Flk-1 levels (n.s.d) in either genotype. Bar graph represents mean (+ s.e.m.) of Flk-1 expression relative to Hsc-70 loading control (N = 3-4 independent experiments). B. HUVEC were transfected with vector only, a wild-type Rac1 construct (Rac1 WT), or a constitutively active Rac1 construct (Rac1 QL) and seeded on confluent fibroblasts. Tubules were visualized by PECAM1 staining 5 days after seeding. The mean number of branch points (+SEM) is shown in the accompanying bar chart. (n = 12 microscopic fields per condition). Scale bar: 100 microm.
###end p 49
###begin p 50
###xml 44 51 44 51 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 223 231 223 231 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 395 399 395 399 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009766-SanzMoreno1">[32]</xref>
###xml 618 619 618 619 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 626 635 626 635 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 9B</bold>
###xml 626 635 626 635 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0009766-g009"><bold>Figure 9B</bold></xref>
###xml 310 315 <span type="species:ncbi:9606">human</span>
Although Rac1 appears dispensable to normal in vivo angiogenesis, the question remained as to whether elevated Rac1-activity could influence angiogenesis. To test whether elevated Rac1-activity influences 3D tube formation in vitro, both WT Rac1 and constitutively active Rac1 (Rac1 QL) were over-expressed in human umbilical endothelial cells (HUVEC) plated on a confluent layer of fibroblasts [32]. Tubules were visualized by PECAM-1 staining after 5 days in culture. The number of branch points in HUVEC overexpressing either form of Rac1 was significantly higher when compared to vector only transfected controls (P<0.02, Figure 9B), demonstrating that elevated Rac1 levels or activity can enhance tube formation.
###end p 50
###begin p 51
###xml 122 127 122 124 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#946;3</bold>
###xml 64 68 <span type="species:ncbi:10090">mice</span>
Overall, our findings suggest that normally (in adult wild-type mice) angiogenesis does not depend on Rac1. However, when beta3-integrin levels are altered, tumor growth, tumor angiogenesis and VEGF-driven angiogenesis are enhanced and dependent on Rac1.
###end p 51
###begin title 52
Discussion
###end title 52
###begin p 53
###xml 100 107 100 107 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 638 643 632 634 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#946;3</bold>
###xml 238 242 <span type="species:ncbi:10090">mice</span>
###xml 559 563 <span type="species:ncbi:10090">mice</span>
Here we describe the role of Rac1 in tumor growth, tumor angiogenesis and VEGF-induced angiogenesis in vivo. Importantly, none of these processes were affected when Rac1 was depleted or deleted in the tumor endothelium of adult wild-type mice. These findings reveal that, unexpectedly, Rac1 expression in adult endothelial cells is not essential for tumor angiogenesis. However, we report that active levels of Rac1 are increased in beta3-null endothelial cells and that the enhanced tumor growth, tumor angiogenesis and VEGF-mediated responses in beta3-null mice were all dependent on endothelial Rac1 expression since Rac1-depletion in beta3-null endothelial cells reduced significantly these responses. These data demonstrate that the requirement for endothelial-Rac1 becomes important when vascular beta3-integrin is absent.
###end p 53
###begin p 54
###xml 186 194 186 194 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 261 268 261 268 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 355 362 355 362 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 429 430 429 430 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 575 582 575 582 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 873 877 873 877 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009766-Sawada1">[24]</xref>
###xml 1006 1010 1006 1010 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009766-Tan1">[25]</xref>
###xml 1304 1308 1304 1308 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009766-Sawada1">[24]</xref>
###xml 1374 1378 1374 1378 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009766-Carmeliet2">[33]</xref>
###xml 1896 1900 1896 1900 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009766-Constien1">[34]</xref>
###xml 1902 1906 1902 1906 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009766-Griffin1">[35]</xref>
###xml 431 435 <span type="species:ncbi:10090">mice</span>
###xml 485 489 <span type="species:ncbi:10090">mice</span>
###xml 798 802 <span type="species:ncbi:10090">mice</span>
###xml 1090 1094 <span type="species:ncbi:10090">mice</span>
###xml 1516 1520 <span type="species:ncbi:10090">mice</span>
###xml 1782 1786 <span type="species:ncbi:10090">mice</span>
Endothelial cell proliferation, migration and tube formation are essential processes during tumor angiogenesis and Rac1 activity is believed to be important for these cellular processes in vitro implying a possible requirement for this molecule in angiogenesis in vivo. However our data demonstrating that tumor angiogenesis and VEGF-induced angiogenesis in vivo were not affected in either pSico-Rac1-infected wild-type/Tie1-Cre+ mice or tamoxifen-treated Rac1 flox/flox PDGFB-iCreER mice, imply that angiogenic processes such as proliferation, migration and tube formation in vivo are not affected by the induced-loss of Rac1 in adult endothelial cells. In contrast, recent studies have suggested a positive role for Rac1 in endothelial cell function. For example, a 50% loss of Rac1 in Tie2-Cre mice results in reduced neovascularization in the hind-limb ischemia model [24]. In addition, Rac1-deletion in Tie2-Cre embryos results in early lethality due to severe heart and vasculogenic defects by E8.5 [25]. The apparent discrepancies between our results and those reported in Tie2-Cre mice may be due to several reasons. For example, the haploinsufficiency or deletion of Rac1 in these systems is from early embryogenesis and this has been shown to induce changes in blood pressure and vasodilation [24] that, in turn, are known to affect neovascularization indirectly [33] and therefore it is likely that such changes in blood pressure would actually affect angiogenesis in the Rac1-haploinsufficient-Tie2-Cre mice. In contrast, using the pSico or PDGFB-iCreER-inducible systems we have deleted Rac1, predominantly, in adult tumor or VEGF-induced neo-endothelial cells themselves, thus reducing any side effects on the whole vasculature. In addition, Cre activity in Tie2-Cre mice, as well as being present in endothelial cells, is also apparent in approximately 80% of hematopoietic cells [34], [35], and it is tempting to speculate that the haploinsufficiency or deletion of Rac1 in this compartment may well affect angiogenesis. In contrast, in the pSico models that we have used, it is unlikely that the hematopoietic compartment is subject to Rac1-deletion and thus these cells are unlikely to affect angiogenesis in our system.
###end p 54
###begin p 55
###xml 179 184 179 181 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#946;3</bold>
###xml 245 249 242 246 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009766-Mettouchi1">[36]</xref>
###xml 493 497 490 494 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009766-Wells1">[37]</xref>
Regarding proliferation, our results corroborate the findings that increased Rac1 activity correlates with enhanced endothelial proliferation, since the elevated Rac1-activity in beta3-null endothelial cells show elevated proliferative capacity [36]. However, our data go on to demonstrate that the loss of Rac1-activity is not sufficient to control microvascular-endothelial cell growth in culture and this is in line with other data where deletion of Rac1 does not affect cell proliferation [37].
###end p 55
###begin p 56
###xml 471 475 471 475 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009766-Garrett1">[38]</xref>
###xml 477 481 477 481 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009766-Soga1">[39]</xref>
###xml 483 487 483 487 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009766-Zeng1">[40]</xref>
###xml 785 792 785 792 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 780 784 <span type="species:ncbi:10090">mice</span>
Our data also illustrate that the requirement for Rac1 in 3D versus 2D endothelial cell migration is different. Indeed, by examining VEGF-induced endothelial cell migration in 2D (scratch wound healing assays) and in 3D (3D modified Boyden chamber assays), Rac1-depleted cells were less motile than controls in 2D; whereas they migrated as well as controls in 3D. Several studies have shown that VEGF-mediated endothelial cell migration in 2D involves activation of Rac1 [38], [39], [40] and our data are in line with these observations. Importantly, however, our findings demonstrate that the involvement of Rac1 in 3D endothelial cell migration is not as critical as originally thought and this is likely to reflect the reason for the normal tumor angiogenesis in Rac1-depleted mice in vivo.
###end p 56
###begin p 57
###xml 141 145 141 145 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009766-Bayless1">[41]</xref>
###xml 147 151 147 151 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009766-Cascone1">[42]</xref>
###xml 153 157 153 157 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009766-Connolly1">[43]</xref>
###xml 159 163 159 163 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009766-Davis1">[44]</xref>
###xml 165 169 165 169 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009766-Davis2">[45]</xref>
###xml 171 175 171 175 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009766-Hoang1">[46]</xref>
###xml 177 181 177 181 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009766-Koh1">[47]</xref>
###xml 412 416 412 416 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009766-Liu1">[48]</xref>
###xml 841 846 841 843 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#946;3</bold>
###xml 882 889 879 886 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
The reduced VEGF-induced 2D tube formation, after Rac1-depletion in endothelial cells, that we observed is also in line with several reports [41], [42], [43], [44], [45], [46], [47]. In contrast, using a novel 3D model involving co-culture with VEGF-A-overexpresing fibroblasts, others have shown that dominant-negative N17Rac1 has no effect on VEGF-induced capillary-like network formation of endothelial cells [48]. These investigators showed that a dominant negative mutant of N-Ras (a small GTPase from a different family to that of Rac1) suppressed capillary-network formation of endothelial cells induced by VEGF-A-producing fibroblasts whereas the mutants of Rac1, RhoA or Cdc42 did not. Our observations also support the notion that, in 3D environments, Rac1 is dispensable for VEGF-mediated capillary-formation in wild-type but not beta3-null aortic rings and angiogenesis in vivo.
###end p 57
###begin p 58
###xml 241 245 231 235 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009766-Dormond1">[49]</xref>
###xml 247 251 237 241 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009766-Ruegg1">[50]</xref>
###xml 913 918 888 890 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#946;3</bold>
Previous studies have suggested that beta3-integrin activation induces Rac1 activity. For example, inhibition of endothelial cell cyclooxygenase-2, by nonsteroidal anti-inflammatory drugs, suppresses alphavbeta3-dependent activation of Rac1 [49], [50]. Given such crosstalk between integrins and Rac1, it is surprising that Rac1-activity is enhanced in beta3-null endothelial cells. The increased active levels of Rac1 may reflect a compensatory response due to the deletion of beta3-integrin, since rescuing the expression of beta3-integrin in beta3-null endothelial cells diminished the activity of Rac1 to levels similar as those seen in wild-type. Importantly, however, the expression and activity levels of other tested Rho-related GTPases (e.g. Rac2, Rac3, Cdc42 and RhoA) were equal in wild-type and beta3-null endothelial cells suggesting that these Rho GTPases are unlikely to compensate for the loss of beta3-integrin.
###end p 58
###begin p 59
###xml 84 88 84 88 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009766-Elfenbein1">[51]</xref>
###xml 188 192 188 192 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009766-Bass1">[52]</xref>
###xml 672 679 666 673 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 934 941 925 932 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 391 395 <span type="species:ncbi:10090">mice</span>
###xml 433 437 <span type="species:ncbi:10090">mice</span>
Although recent work has shown that molecules such as RhoG can compensate for Rac-1 [51] there is also evidence that this depends on specific signaling cascades and is not always the case [52]. Our data suggest that this is unlikely in beta3-null endothelial cells, since we have shown, that by inhibiting Rac1 expression alone, we can reduce the enhanced angiogenic responses of beta3-null mice back to levels observed in wild-type mice either with or without depletion of Rac1. Although it is tempting to speculate that RhoG activity may compensate for Rac1 in wild-type endothelial cells, thus explaining the reduced requirement for Rac1 in wild-type angiogenic events in vivo, this is also not likely because Rac1-deletion in both beta3-null and wildtypes brings tumor growth and blood vessel density to the same level in both genotypes. Thus the most logical assumption is simply that Rac1 is not involved in tumor angioegenesis in vivo unless beta3-integrin is absent.
###end p 59
###begin p 60
###xml 93 98 93 95 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#946;3</bold>
###xml 314 318 <span type="species:ncbi:10090">mice</span>
Our data indicate that the importance of Rac1 in angiogenic processes is revealed only after beta3-integrin is absent. We show that the enhanced Rac1 activity in beta3-null endothelial cells is responsible, at least in part, for the elevated tumor angiogenesis and VEGF-mediated angiogenic responses in beta3-null mice.
###end p 60
###begin p 61
###xml 87 91 84 88 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009766-Reynolds1">[12]</xref>
###xml 93 97 90 94 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009766-Reynolds2">[27]</xref>
###xml 99 103 96 100 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009766-Robinson1">[53]</xref>
Despite the fact that beta3-null endothelial cells have elevated VEGFR2 (Flk-1) levels [12], [27], [53], even after Rac1-depletion, indicates that elevated VEGFR2 levels alone are not sufficient to enhance angiogenesis. We show that VEGF/VEGFR2-mediated responses are Rac1-dependent in the absence, but not in the presence of beta3-integrin, raising the possibility that downstream signalling of VEGFR2 can either involve Rac1 or not, but that this depends on beta3-integrin.
###end p 61
###begin p 62
###xml 3 8 3 5 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#946;3</bold>
###xml 222 227 219 221 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#946;3</bold>
###xml 350 354 344 348 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009766-Engl1">[54]</xref>
###xml 356 360 350 354 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009766-Laferriere1">[55]</xref>
###xml 362 366 356 360 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009766-Rousseau1">[56]</xref>
###xml 471 476 465 467 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#946;3</bold>
###xml 14 18 <span type="species:ncbi:10090">mice</span>
In beta3-null mice the increased Rac1-1 activity likely results in changes in downstream signaling that confer the enhanced angiogenic responses. For example, p38 MAP kinase signaling is known to be downstream of Rac1 and beta3-integrin and plays a role in angiogenic processes such as endothelial cell migration and regulation of cell-cell adhesion [54], [55], [56]. Thus, in future experiments it would be of interest to examine the role of p38 MAP-kinase signaling in beta3-null endothelial cells.
###end p 62
###begin p 63
###xml 214 218 207 211 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009766-HodivalaDilke1">[57]</xref>
###xml 295 298 288 291 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009766-Gutheil1">[5]</xref>
###xml 338 341 331 334 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009766-Eskens1">[3]</xref>
###xml 343 346 336 339 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009766-Friess1">[4]</xref>
###xml 348 351 341 344 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009766-Hariharan1">[6]</xref>
###xml 353 356 346 349 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009766-Nabors1">[7]</xref>
###xml 548 551 541 544 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009766-Eskens1">[3]</xref>
###xml 553 556 546 549 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009766-Friess1">[4]</xref>
###xml 558 561 551 554 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009766-Hariharan1">[6]</xref>
###xml 563 566 556 559 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009766-Stupp1">[9]</xref>
###xml 568 572 561 565 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009766-Tucker1">[10]</xref>
###xml 574 578 567 571 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009766-Ellis1">[11]</xref>
###xml 679 684 668 670 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#946;3</bold>
###xml 885 889 868 872 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009766-Mechtersheimer1">[16]</xref>
###xml 1065 1069 1045 1049 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009766-Sato1">[17]</xref>
###xml 1071 1075 1051 1055 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009766-Sato2">[18]</xref>
###xml 162 167 <span type="species:ncbi:10090">mouse</span>
###xml 541 547 <span type="species:ncbi:9606">humans</span>
###xml 755 760 <span type="species:ncbi:9606">human</span>
###xml 1185 1193 <span type="species:ncbi:9606">patients</span>
Several studies have shown that the blockade of alphavbeta3 using monoclonal antibodies or antagonist peptides can inhibit tumor growth and tumor angiogenesis in mouse xenografts models and other preclinical tests [57] and some of these agents, such as the humanized monoclonal antibody Vitaxin [5] and the cyclic RGD peptide Cilengitide [3], [4], [6], [7] are in clinical trials for the anti-angiogenic treatment of cancer. However, to date, there is very little evidence showing these inhibitors can in fact suppress tumor angiogenesis in humans [3], [4], [6], [9], [10], [11]. This may simply reflect that tumor angiogenesis is not actually dependent on the activity of alphavbeta3-integrin in endothelial cells in several tumor types. Indeed, in some human tumors, such as angiosarcomas, endothelial beta3-integrin expression levels decrease as malignant transformation progresses [16]. In addition, vascular beta3-integrin levels were significantly lower in lung metastases from colorectal carcinomas when compared with those seen in primary colorectal tumors [17], [18]. Thus, targeting beta3-integrin might not be a useful anti-angiogenic strategy for this particular subset of patients.
###end p 63
###begin p 64
###xml 202 206 196 200 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009766-Pampori1">[58]</xref>
###xml 284 291 278 285 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 330 337 321 328 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 539 543 524 528 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009766-Reynolds1">[12]</xref>
###xml 634 642 616 624 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 816 820 795 799 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009766-Stupack1">[59]</xref>
###xml 1126 1130 1099 1103 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009766-Reynolds3">[60]</xref>
###xml 1291 1298 1261 1268 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 1341 1345 <span type="species:ncbi:10090">mice</span>
One question that remains unanswered is: "when is beta3-integrin actually bound to ligand during the angiogenic process?" Wow-1 is an antibody that recognizes ligated beta3 integrin in cells in culture [58] but, unfortunately, has yet to be proven to work in whole tissue sections or in vivo. Thus testing beta3-integrin ligation in vivo is presently impossible without the use of inhibitors. Importantly, since inhibition of beta3-ligation does not phenocopy the deficiency of beta3-integrin, where such angiogenic responses are enhanced [12], it is also not possible to test whether beta3-integrin ligation is truly relevant to our in vitro findings. This is because inhibition of beta3-ligation, using RGD mimetics or antibodies, can inhibit tubule formation, for many reasons including an increase in cell death [59]. Thus inhibiting beta3-integrin function not only inhibits beta3-ligation but also simultaneously alters downstream signaling. Furthermore, we have recently shown that low doses of such agents can actually enhance angiogenesis, both in vitro and in vivo, but that these doses do not affect ligand binding [60]. Thus in conclusion, although such experiments would be of great interest we await the technology to enable us to test the effect of beta3-ligation effectively in vivo without the use of inhibitors or knockout mice.
###end p 64
###begin p 65
Our findings suggest that inhibition of Rac1 might be an effective anti-angiogenic therapeutic strategy in tumor blood vessels that display low levels of beta3-integrin. Furthermore, combination therapy of anti-Rac1 and anti-beta3-integrin targeted to endothelial cells may be an effective general anti-angiogenic strategy.
###end p 65
###begin title 66
Materials and Methods
###end title 66
###begin title 67
Ethics Statement
###end title 67
###begin p 68
###xml 18 22 <span type="species:ncbi:10090">mice</span>
All procedures on mice were performed in accordance with the United Kingdom Home Office regulations.
###end p 68
###begin title 69
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
Mice
###end title 69
###begin p 70
###xml 93 100 90 97 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 153 157 147 151 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009766-HodivalaDilke2">[61]</xref>
###xml 208 212 202 206 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009766-Gustafsson1">[62]</xref>
###xml 588 596 577 585 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 775 779 764 768 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009766-Walmsley1">[28]</xref>
###xml 849 853 838 842 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009766-Claxton1">[29]</xref>
###xml 48 52 <span type="species:ncbi:10090">mice</span>
###xml 172 176 <span type="species:ncbi:10090">mice</span>
###xml 191 206 <span type="species:ncbi:10090">transgenic mice</span>
###xml 386 390 <span type="species:ncbi:10090">mice</span>
###xml 660 664 <span type="species:ncbi:10090">mice</span>
###xml 737 741 <span type="species:ncbi:10090">mice</span>
###xml 798 813 <span type="species:ncbi:10090">transgenic mice</span>
beta3-integrin-deficient and wild-type Tie1-Cre mice used for analysis of pSico lentiviruses in vivo were generated by crossing beta3-integrin-deficient [61] and wild-type mice with Tie1-Cre transgenic mice ([62]; kindly provided by Prof. Fassler, Max Plank Institute of Biochemistry, Martinsried, Germany), both on a mixed C57BL6/129 background. beta3-integrin-deficient and wild-type mice were also bred with the Immortomouse(R) (Charles River Laboratories, MA, USA) on a C57BL6 background and were used for preparation of immortalised endothelial cell cultures employed in some of the in vitro assays. Inducible vascular endothelium-specific Rac1-deficient mice (Rac1 flox/flox PDGFB-iCreER) were generated by crossing Rac1 flox/flox mice on a mixed C57BL6/129 background [28] with PDGFB-iCreER transgenic mice on a mixed C57BL6/CBAF2 background [29].
###end p 70
###begin title 71
###xml 13 18 <span type="species:ncbi:10090">mouse</span>
Isolation of mouse endothelial cells
###end title 71
###begin p 72
###xml 73 77 73 77 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009766-Reynolds4">[63]</xref>
###xml 0 5 <span type="species:ncbi:10090">Mouse</span>
###xml 483 486 <span type="species:ncbi:10116">rat</span>
###xml 492 497 <span type="species:ncbi:10090">mouse</span>
###xml 587 590 <span type="species:ncbi:10116">rat</span>
###xml 596 601 <span type="species:ncbi:10090">mouse</span>
Mouse lung endothelial cells (MLEC) were isolated as previously reported [63]. Briefly, minced lungs were digested in collagenase type 1 (Gibco) and passed trough a 70 microm pore size cell strainer (BD Falcon) and cell suspension plated onto tissue culture plates coated with 0.1% gelatin containing 10 microg/ml fibronectin (Sigma) and 30 microg/ml Purecol (Nutacon). When cells reached approximately80% confluency, macrophages were removed from the culture by immunosorting using rat anti-mouse CD16/CD32 Fcgamma receptor antibodies (AbD Serotech) and with two subsequent sorts using rat anti-mouse ICAM-2 antibodies (AbD Serotech) endothelial cells were positively selected. Endothelial cell purity was 96-98% as assessed by performing flow cytometry for PECAM-1 (clone MEC 13.3, Pharmingen), Endoglin (Pharmingen) and ICAM-2 expression. Acquisition of samples was performed on a FACS Calibur fluorescence activated cell sorter (BD Biosciences) and the data were analysed with CELLQUEST software (BD Biosciences). Cells were cultured routinely in a 50:50 mix of Hams F12 and D-MEM media supplemented with 20% FCS, 6 mM glutamine, 25 microg/ml endothelial mitogen (Biogenesis), 1 microg/ml heparin and antibiotics.
###end p 72
###begin title 73
Generation of pSico-Rac1 lentivirus
###end title 73
###begin p 74
###xml 4 5 4 5 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</underline>
###xml 16 17 16 17 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S</underline>
###xml 27 28 27 28 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">i</underline>
###xml 40 42 40 42 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">co</underline>
###xml 146 150 146 150 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009766-Ventura1">[64]</xref>
###xml 780 784 780 781 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#946;</italic>
###xml 795 799 792 796 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009766-Robinson2">[65]</xref>
###xml 324 329 <span type="species:ncbi:10090">mouse</span>
###xml 558 563 <span type="species:ncbi:10090">mouse</span>
###xml 748 753 <span type="species:ncbi:10090">mouse</span>
###xml 760 765 <span type="species:ncbi:10090">mouse</span>
###xml 948 953 <span type="species:ncbi:10090">mouse</span>
###xml 1018 1023 <span type="species:ncbi:10090">mouse</span>
###xml 1108 1115 <span type="species:ncbi:110766|species:ncbi:562">E. coli</span>
The plasmid for Stable RNA interference conditional (pSico) was a kind gift from Dr. Tyler Jacks (Massachusetts Institute of Technology, MA, USA) [64]. The pSico-Rac1 lentiviral vector was produced by digesting the pSico construct with HpaI-XhoI restriction enzymes (Promega), inserting shRNA oligonucleotides to target the mouse Rac1 gene and religating using T4 DNA ligase (Promega). A pSico containing shRNA to target the firefly Luciferase gene (pSico-Con) was generated to serve as a non-specific control RNAi and a pSico containing shRNA to target the mouse VEGFR2/Flk-1 gene (pSico-Flk-1) was made to stably knockdown the expression of Flk-1, therefore serving as a positive control in angiogenesis assays. Oligonucleotides coding shRNA for mouse Rac1, mouse VEGFR2/Flk-1, beta3-integrin [65] and firefly Luciferase were designed using the program PSICOLIGOMAKER 1.5 (available on Jacks' website). Luciferase oligos were blasted against the mouse genome to ensure that they do not recognise any sequence in the mouse DNA. All oligonucleotide sequences are available upon request. Chemically competent E. coli (One Shot Stbl3, Invitrogen) were transformed with ligated DNA. Plasmids were purified (QIAprep kit, Quiagen), digested with SacII-NotI (Promega) and positive clones released a fragment approximately 50 bp larger than the fragment released by pSico empty vector. Positive clones were sequence verified (Equipment Park Laboratory, London Research Institute Cancer Research UK). Sequences were analysed using DNA Strider 1.4f1 software (CEA, France).
###end p 74
###begin p 75
###xml 1599 1600 1587 1588 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 520 525 <span type="species:ncbi:10090">mouse</span>
Lentiviruses were generated essentially as described in the Virapower Lentiviral Expression System User Manual (Invitrogen). Briefly, 3 microg of pSico-Rac1, pSico-Con or pSico-Flk-1 lentiviral vectors and 9 microg of ViraPower Packaging Mix (Invitrogen) were cotransfected in 293FT cells (Invitrogen) by using Lipofectamine 2000 reagent (Invitrogen). Supernatants were collected 48-72 hr after transfection, centrifuged at 3000 rpm for 15 min, filtered through a 0.45 microm filter, and used to directly infect primary mouse lung endothelial cells. Overnight infection usually was sufficient to infect 50-65% of the cells as assessed by flow cytometry. Acquisition of samples was performed on a FACS Calibur fluorescence activated cell sorter (BD Biosciences) and the data were analysed with CELLQUEST software (BD Biosciences). GFP-positive endothelial cells were sorted 3-4 days after transfection using a FACSAria cell sorter and program. Sorted cells were used to assess efficiency of Cre-mediated RNAi in vitro by transfecting them with Cre expression-plasmid, pTURBO-Cre (a kind gift from Dr. David Stevenson, The Beatson Institute, UK). Transfection of cells was performed by electroporation using the Basic Nucleofector kit designed for primary mammalian endothelial cells (Amaxa GmbH) following the manufacturer's instructions. One week after transfection with pTURBO-Cre, Rac1 and Flk-1 knockdown efficiencies were assessed by RT-PCR and Western blotting. For in vivo experiments, lentivirus were ultracentrifuged at 25000x g for 1.5 hr and stocks titrated. Titers ranged between 1.5-2x106 i.u/ml.
###end p 75
###begin title 76
Rac1 siRNA
###end title 76
###begin p 77
###xml 10 15 <span type="species:ncbi:10090">mouse</span>
###xml 117 122 <span type="species:ncbi:10090">mouse</span>
###xml 176 181 <span type="species:ncbi:10090">mouse</span>
To target mouse Rac1 gene we used siGENOME ON-TARGETplus SMARTpool reagent (Dharmacon). Primary and immorto MLEC and mouse aortic tissue (see below) were transfected with anti-mouse Rac1 siRNA using Oligofectamine reagent (Invitrogen) following the manufacturer's instructions. The final concentration of oligonucleotides in the transfection mixture was 100 nM and gene expression was examined 48 hr (MLEC) or 5 days (aortic tissue) post-transfection by RT-PCR and Western Blot analysis. In all transfection experiments scrambled siRNA (Dharmacon)-transfected samples were used as controls.
###end p 77
###begin title 78
Semiquantitative RT-PCR
###end title 78
###begin p 79
###xml 127 131 127 131 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009766-Wells1">[37]</xref>
###xml 56 61 <span type="species:ncbi:10090">mouse</span>
We used Rac1 isoform-specific primers derived from cDNA mouse sequences and PCR conditions that have been described previously [37]. As controls of the Rac2 and Rac3 reactions, total RNA and subsequent cDNA synthesis from spleen and brain tissues were obtained. Actin RT-PCR was performed as a loading control.
###end p 79
###begin title 80
Western blot analysis
###end title 80
###begin p 81
###xml 706 711 <span type="species:ncbi:10090">mouse</span>
###xml 745 750 <span type="species:ncbi:10090">mouse</span>
###xml 774 779 <span type="species:ncbi:10090">mouse</span>
###xml 806 812 <span type="species:ncbi:9986">rabbit</span>
###xml 1301 1306 <span type="species:ncbi:10090">mouse</span>
Cells were grown to approximately80% confluency and lysed with RIPA buffer (50 mM Tris-HCl pH 7.4, 1% NP-40, 0.25% sodium deoxycholate, 150 mM NaCl, 1 mM EDTA, 1 mM sodium orthovanadate, 1 mM NaF, 1 mM PMSF), supplemented with protease inhibitor cocktail II (Calbiochem). For preparation of lysates from aortas, 12-15 aortic rings were homogenised in 50 ml RIPA buffer by using a pestle and microwaved for 10-15 sec. Homogenates were centrifuged at 10,000 rpm for 10 min at 4degreesC, to pellet insoluble material. Lysates were subjected to SDS-PAGE and transferred to membranes (Hybond-ECL, Amersham Biosciences). Membranes were blocked in either 5% milk or 5% BSA in PBS-Tween (0.05%) and incubated with mouse anti-Rac1 (Clone 23A8, Upstate), mouse anti-Cdc42 (Chemicon), mouse anti-RhoA (Santa Cruz) or rabbit anti-VEGFR2 (Cell Signalling Technologies) antibodies. Membranes were washed three times in PBS-Tween (0.05%) and subsequently incubated with HRP-conjugated IgGs. Immunoreactive bands were visualised by incubating the membranes with ECL chemiluminescence reagents (Amersham Life Science) and exposing the membranes to autoradiography film (Amersham Life Science). After detection of the protein of interest, membranes were stripped with stripping solution (Chemicon), and re-blotted with mouse anti-Hsc-70 antibody. Densitometry was performed using a gel acquisition and analysis set-up (UV Products, Ltd.). Band densities were normalised to Hsc-70 to make quantitative measurements of the protein of interest.
###end p 81
###begin title 82
Rho GTPases activity assays
###end title 82
###begin p 83
###xml 399 403 399 403 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009766-Nystrom1">[66]</xref>
###xml 910 912 910 912 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TM</sup>
###xml 946 948 946 948 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TM</sup>
A construct encoding glutathione S-transferase (GST) linked to the amino acid residues 57 to 141 of the PAK-CRIB domain (GST-PAK-CRIB; kindly provided by Dr. John Collard, King's College, London, UK and Dr. Vania Braga, Imperial College, London, UK), was used to pull down active Rac1 and Cdc42 from MLEC cell lysates transfected with scrambled or Rac1 siRNA. Pull-downs were performed as described [66]. Samples of lysate preincubation (total protein) and postincubation with the GST-PAK-CRIB beads (active protein) were resolved in 12% polyacrylamide gels, transferred to PVDF membranes, and immunoblotted with anti-Rac1 or anti-Cdc42 antibodies as described above. The proportion of active Rac1 and Cdc42 relative to their the total amount in the cells was determined by densitometry (UV Products, Ltd.). Active levels of RhoA in MLEC transfected with scrambled or Rac1 siRNA, were assessed using the G-LISATM RhoA activation assay Biochem KitTM (Cystoskeleton) following the manufacturer's instructions. The degree of RhoA activation was determined by comparing absorbance readings at 490 nm from Rho control protein (constitutively active RhoA protein) samples versus cell lysates of interest.
###end p 83
###begin title 84
In vivo tumorigenesis and endothelial-specific Rac1-deletion
###end title 84
###begin p 85
###xml 277 278 277 278 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 47 51 <span type="species:ncbi:10090">mice</span>
Rac1 flox/flox and Rac1 flox/flox PDGFB-iCreER mice were implanted subcutaneously with tamoxifen (Rac1 flox/flox and Rac1 flox/flox PDGFB-iCreER) or placebo (Rac1 flox/flox PDGFB-iCreER) 1 mg-slow release pellets in the scruff of the neck. One day later B16F0 tumor cells (1x106) were injected subcutaneously in the flank. At day 10 after tumor cell injections, tumors were dissected out and processed for histology.
###end p 85
###begin title 86
In vivo VEGF-induced angiogenesis assays
###end title 86
###begin p 87
###xml 46 50 46 50 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009766-Andrade1">[67]</xref>
###xml 356 357 349 350 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 471 472 460 461 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 984 985 962 963 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 0 5 <span type="species:ncbi:10090">Mouse</span>
###xml 184 188 <span type="species:ncbi:10090">mice</span>
###xml 445 449 <span type="species:ncbi:10090">mice</span>
###xml 705 709 <span type="species:ncbi:10090">mice</span>
###xml 958 962 <span type="species:ncbi:10090">mice</span>
Mouse subcutaneous sponge angiogenesis assays [67] were carried out by implanting two autoclaved sponges subcutaneously into the flanks of wild-type/Tie1-Cre+ and beta3-null/Tie1-Cre+ mice. Sponges were injected in situ as follows: on days 1, 5 and 9 with 100 microl of 10 ng/ml VEGF-A164; on days 3, 7 and 13 with pSico-Con, pSico-Rac1 and pSico-Flk-1 (106 i.u/ml) in 100 microl of 10 ng/ml VEGF-A164. At day 15 after sponge implantations, the mice were euthanized by CO2 asphyxiation, sponges excised and fixed for paraffin embedding. Additionally growth factor induced angiogenesis assays were carried out by implanting two autoclaved sponges subcutaneously into the flanks of wild-type and beta3-null mice. These sponges were further injected in situ every 2 days with Con siRNA (3 mg) in 100 microl of PBS alone, Con siRNA (3 mg) or Rac1 specific-siRNA (3 mg) in 100 microl of PBS containing 10 ng/ml VEGF-A164. At day 15 after sponge implantation, the mice were euthanized by CO2 asphyxiation, sponges excised and processed for histology.
###end p 87
###begin title 88
Quantification of blood vessel density
###end title 88
###begin p 89
###xml 1224 1225 1224 1225 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1229 1230 1229 1230 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 1241 1242 1241 1242 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 386 389 <span type="species:ncbi:10116">rat</span>
###xml 395 400 <span type="species:ncbi:10090">mouse</span>
###xml 423 429 <span type="species:ncbi:9986">rabbit</span>
###xml 484 487 <span type="species:ncbi:10116">rat</span>
###xml 493 498 <span type="species:ncbi:10090">mouse</span>
###xml 646 650 <span type="species:ncbi:9925">goat</span>
###xml 656 659 <span type="species:ncbi:10116">rat</span>
###xml 677 681 <span type="species:ncbi:9925">goat</span>
###xml 687 693 <span type="species:ncbi:9986">rabbit</span>
###xml 750 756 <span type="species:ncbi:9986">rabbit</span>
###xml 762 765 <span type="species:ncbi:10116">rat</span>
Tumor and sponge samples were snap frozen for cryosectioning or fixed in 4% paraformaldehyde for paraffin-embedding, respectively. Frozen sections were brought to room temperature, fixed in 4% PFA and rehydrated in PBS, whilst paraffin embedded sections were deparaffinized, rehydrated in PBS and microwaved on full power (950 W) in sodium citrate buffer pH 6.0, before incubation with rat anti-mouse PECAM-1 (Pharmingen), rabbit anti-green fluorescent protein (GFP) (Mol Probes) and rat anti-mouse endomucin (kindly provided by Dr. Dietmar Vestweber, Max-Planck-Institute of Molecular Biomedicine, Muenster, Germany) followed by incubation with goat anti-rat Alexa Fluor-546, goat anti-rabbit Alexa Fluor-488 (both from Mol Probes) and biotinylated rabbit anti-rat antibody (Vector Laboratories), respectively. When biotinylated antibody was used an alkaline phosphatase-based system (VECTASTAIN ABC-AP, Vector Laboratories, Peterborough, UK) with Vector Blue substrate kit (Vector Laboratories, Peterborough, UK) was used to amplify the signal according to the manufacturer's instructions. Blood vessel density in immunofluorescent stained sections from size-matched tumors was determined by counting the number of PECAM-1+/GFP- or PECAM-1+ blood vessels present across an entire section and then dividing by the total area of the section. Blood vessel density in immuno alkaline-phosphatase stained sections from sponges was determined by counting the number of endomucin+/GFP- stained blood vessels present across an entire section and then dividing by the total area of the section. In all cases blood vessel counting was performed in a double-blind fashion using an epifluorescence microscope Zeiss (Carl Zeiss, Jena, Germany) with associated digital camera (Hamamatsu Photonics, Ltd., Welwyn Garden City, UK) and using Open Lab software v4.1software (Improvission, Coventry, UK) to capture images and calculate areas of the sections.
###end p 89
###begin title 90
###xml 8 13 <span type="species:ncbi:10090">mouse</span>
Ex vivo mouse aortic ring assays
###end title 90
###begin p 91
###xml 618 622 607 611 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009766-Reynolds2">[27]</xref>
###xml 788 789 767 768 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 39 43 <span type="species:ncbi:10090">mice</span>
Wild-type and beta3-integrin-deficient mice were sacrificed by cervical dislocation, thoracic aortas removed under sterile conditions, periaortic fibroadipose tissue was removed and aortas were cut into 0.5-1 mm-wide rings. After 24 hours siRNA transfected aortic rings were rinsed in D-MEM supplemented with 6 mM L-glutamine and 2% FCS (basal medium) and each ring was transferred to a well of a 96-well plate containing polymerized growth factor reduced (GFR)-Matrigel (Becton Dickson, Beds, UK) before adding 150 microl of basal medium. The medium was supplemented with 25 ng/ml VEGF-A164 and DC101 at 20 microg/ml [27]. Where DC101 was used, the GFR-Matrigel was supplemented with 20 microg/ml DC101 antibody just before polymerisation. The cultures were grown at 37degreesC and 8% CO2, for up to 8 days. Aortic rings were examined microscopically and media including VEGF and DC101 was changed every 2 days. On day 5, phase contrast photomicrographs were taken using an inverted microscope (Carl Zeiss) equipped with a camera (Hamamatsu Photonics, Ltd.) and angiogenesis calculated by counting the number of capillary sprouts per ring. Rac1 expression in transfected aortic rings was assessed by using both semiquantitative RT-PCR and Western blot analysis.
###end p 91
###begin title 92
HUVEC Tubule Formation Assay
###end title 92
###begin p 93
###xml 44 48 44 48 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009766-Abraham1">[68]</xref>
###xml 87 91 87 91 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009766-SanzMoreno1">[32]</xref>
These assays were performed as described in [68]. The constructs used are described in [32].
###end p 93
###begin title 94
###xml 0 5 <span type="species:ncbi:10090">Mouse</span>
Mouse lung endothelial cell growth
###end title 94
###begin p 95
###xml 60 65 <span type="species:ncbi:10090">mouse</span>
Temperature-sensitive immortalised wild-type and beta3-null mouse lung endothelial cells were plated at density of 1,500 per square centimetre on pre-coated tissue culture plastic. siRNA transfections were performed and cells were allowed to continue growing. Cells were trypsinized from triplicate wells every day for up to three days and counted using a haemocytometer (Fast Read 102 cell counting chamber [ISL, Paignton, UK]). Cell viability was assayed by Trypan blue exclusion method.
###end p 95
###begin title 96
Wound closure scratch assays
###end title 96
###begin p 97
Wound closure scratch assays were performed as described (21). Briefly, immortalised beta3-null and wild-type MLEC were plated at a density of 10,000 per square centimetre on pre-coated tissue culture plastic. siRNA transfections were performed and cells were grown until a confluent monolayer was achieved. Cells were serum starved for 3 hr, monolayers scratched with a P200 tip, and the scratches were photographed using an inverted microscope (Carl Zeiss Axioplan) equipped with a camera (Hamamatsu Photonics, Ltd.) at three points along their length. The medium was changed for 50:50 mix DMEM:Hams F12 plus glutamine supplemented with VEGF-A164 (25 ng/ml) and cells allowed to migrate over 8 hr at 37degreesC. Scratches were rephotographed, and the percentage of migration was determined relative to the scratch width at 0 hr.
###end p 97
###begin title 98
Modified Boyden chamber assays: 3D migration assay
###end title 98
###begin p 99
###xml 972 973 943 944 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
One day before setting up the 3D migration assays, Con- and Rac1- siRNA transfected beta3-null and wild-type and immortalised MLEC were treated with 4 microg/ml Mitomycin C (Sigma, Dorset, UK) at 37degreesC for 2 hr, to avoid changes in cell proliferation. Cells were washed twice in PBS and serum starved overnight in D-MEM:Ham's F12 plus L-glutamine. Matrix solution was prepared by mixing 1 part of GFR-Matrigel with 1 part of D-MEM:Ham's F12 media. 70 microl of matrix solution was pipetted into the upper well of the transwell (Costar, MA, USA) and incubated at 37degreesC for at least 60 min. D-MEM:Ham's F12 plus L-glutamine and 2.5% FCS supplemented with growth factor alone or growth factor and inhibitor (VEGF-A164 [25 ng/ml] and DC101 [50 ng/ml]) were pipetted into the 'lower chamber'. Cells resuspended in D-MEM:Ham's F12 plus L-glutamine and 2.5% FCS at 50000-75000 per transwell were seeded onto the 'top chamber' and allowed to migrate at 37degreesC, 8% CO2 for 72 hr. Analysis of migrating cells was carried out by counting the number of cells that passed through the transwell after that period. In each experiment, each sample/condition was always assessed in quadruplicate.
###end p 99
###begin title 100
Endothelial tube-like cord formation
###end title 100
###begin p 101
Wild-type and beta3-null immortalised Mock, Con- and Rac1-siRNA transfected MLEC were starved overnight in 1% FCS in DMEM:Hams F12 plus glutamine. GFR-Matrigel was diluted 1:1 in DMEM:Hams F12 plus glutamine on ice, mixed or not with VEGF-A164 at 25 ng/ml final concentration, pipetted onto 10 mm glass coverslips and incubated at 37degreesC for 30 min. Cells at 120,000 cells/ml in DMEM:Hams F12 plus glutamine were plated per well/coverslip and incubated at 37degreesC. Every two hours cells were observed under an inverted microscope (Carl Zeiss Axioplan) equipped with a camera (Hamamatsu Photonics, Ltd.), and photographed. Branch points of developing tubular structures were counted and compared at 8 hr time-point.
###end p 101
###begin title 102
Analysis of Statistical Significance
###end title 102
###begin p 103
Data sets were analysed for significance using Student's t test. P<0.05 was considered statistically significant. Experiments were carried out in a double blind fashion and all experiments were performed in triplicate.
###end p 103
###begin p 104
###xml 96 100 <span type="species:ncbi:10090">mice</span>
We would like to thank Reinhart Faessler (MaxPlank, Germany) for providing us with the Tie1-Cre mice; Tyler Jacks (MIT, USA) and David Stevenson (The Beatson Institute, UK) for the pSico and pTURBO-Cre constructs, respectively; Dietmar Vestweber (MaxPlank, Germany) for the endomucin antibody; John Collard (King's College, UK) for the GST-PAK-CRIB construct and Vania Braga (Imperial College, UK) for technical advice with its use in pull-downs; and Ian Hart (Bart's and The London, Queen Mary's School of Medicine and Dentistry, London, UK) for his help in the preparation of this manuscript.
###end p 104
###begin title 105
References
###end title 105
###begin article-title 106
Angiogenesis in life, disease and medicine.
###end article-title 106
###begin article-title 107
Integrins: the keys to unlocking angiogenesis.
###end article-title 107
###begin article-title 108
###xml 183 191 <span type="species:ncbi:9606">patients</span>
Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins alphavbeta3 and alphavbeta5 in patients with advanced solid tumours.
###end article-title 108
###begin article-title 109
A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer.
###end article-title 109
###begin article-title 110
Targeted antiangiogenic therapy for cancer using Vitaxin: a humanized monoclonal antibody to the integrin alphavbeta3.
###end article-title 110
###begin article-title 111
###xml 157 165 <span type="species:ncbi:9606">patients</span>
Assessment of the biological and pharmacological effects of the alpha nu beta3 and alpha nu beta5 integrin receptor antagonist, cilengitide (EMD 121974), in patients with advanced solid tumors.
###end article-title 111
###begin article-title 112
###xml 56 64 <span type="species:ncbi:9606">patients</span>
Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma.
###end article-title 112
###begin article-title 113
Clinical translation of angiogenesis inhibitors.
###end article-title 113
###begin article-title 114
Integrin inhibitors reaching the clinic.
###end article-title 114
###begin article-title 115
Integrins: molecular targets in cancer therapy.
###end article-title 115
###begin article-title 116
Pathways mediating resistance to vascular endothelial growth factor-targeted therapy.
###end article-title 116
###begin article-title 117
###xml 38 42 <span type="species:ncbi:10090">mice</span>
Enhanced pathological angiogenesis in mice lacking beta3 integrin or beta3 and beta5 integrins.
###end article-title 117
###begin article-title 118
Integrin signaling is critical for pathological angiogenesis.
###end article-title 118
###begin article-title 119
###xml 138 143 <span type="species:ncbi:10090">mouse</span>
The beta3 integrin gene is expressed at high levels in the major haematopoietic and lymphoid organs, vascular system, and skeleton during mouse embryo development.
###end article-title 119
###begin article-title 120
Physiological levels of tumstatin, a fragment of collagen IV alpha3 chain, are generated by MMP-9 proteolysis and suppress angiogenesis via alphaV beta3 integrin.
###end article-title 120
###begin article-title 121
Differential expression of beta 1, beta 3, and beta 4 integrin subunits in nonneoplastic neural cells of the peripheral and autonomic nervous system and in tumors derived from these cells.
###end article-title 121
###begin article-title 122
Vascular integrin beta 3 and its relation to pulmonary metastasis of colorectal carcinoma.
###end article-title 122
###begin article-title 123
Ets-1 and integrin beta3 for lung metastasis from colorectal cancer.
###end article-title 123
###begin article-title 124
###xml 137 142 <span type="species:ncbi:9606">human</span>
Quantitative gene-expression of the tumor angiogenesis markers vascular endothelial growth factor, integrin alphaV and integrin beta3 in human neuroendocrine tumors.
###end article-title 124
###begin article-title 125
Rho GTPases: biochemistry and biology.
###end article-title 125
###begin article-title 126
What tangled webs they weave: Rho-GTPase control of angiogenesis.
###end article-title 126
###begin article-title 127
Multifaceted role of Rho proteins in angiogenesis.
###end article-title 127
###begin article-title 128
Role of small GTPases in endothelial cytoskeletal dynamics and the shear stress response.
###end article-title 128
###begin article-title 129
Regulation of endothelial nitric oxide synthase and postnatal angiogenesis by Rac1.
###end article-title 129
###begin article-title 130
An essential role for Rac1 in endothelial cell function and vascular development.
###end article-title 130
###begin article-title 131
Endothelial cell migration during angiogenesis.
###end article-title 131
###begin article-title 132
###xml 131 135 <span type="species:ncbi:10090">mice</span>
Elevated Flk1 (vascular endothelial growth factor receptor 2) signaling mediates enhanced angiogenesis in beta3-integrin-deficient mice.
###end article-title 132
###begin article-title 133
Critical roles for Rac1 and Rac2 GTPases in B cell development and signaling.
###end article-title 133
###begin article-title 134
Efficient, inducible Cre-recombinase activation in vascular endothelium.
###end article-title 134
###begin article-title 135
Smurf1 regulates tumor cell plasticity and motility through degradation of RhoA leading to localized inhibition of contractility.
###end article-title 135
###begin article-title 136
Differing modes of tumour cell invasion have distinct requirements for Rho/ROCK signalling and extracellular proteolysis.
###end article-title 136
###begin article-title 137
Rac activation and inactivation control plasticity of tumor cell movement.
###end article-title 137
###begin article-title 138
Angiogenesis in health and disease.
###end article-title 138
###begin article-title 139
###xml 42 47 <span type="species:ncbi:10090">mouse</span>
###xml 107 112 <span type="species:ncbi:10090">mouse</span>
Characterization of a novel EGFP reporter mouse to monitor Cre recombination as demonstrated by a Tie2 Cre mouse line.
###end article-title 139
###begin article-title 140
The chromatin-remodeling enzyme BRG1 plays an essential role in primitive erythropoiesis and vascular development.
###end article-title 140
###begin article-title 141
Integrin-specific activation of Rac controls progression through the G(1) phase of the cell cycle.
###end article-title 141
###begin article-title 142
Rac1-deficient macrophages exhibit defects in cell spreading and membrane ruffling but not migration.
###end article-title 142
###begin article-title 143
VEGF-induced Rac1 activation in endothelial cells is regulated by the guanine nucleotide exchange factor Vav2.
###end article-title 143
###begin article-title 144
Rac regulates vascular endothelial growth factor stimulated motility.
###end article-title 144
###begin article-title 145
KDR stimulates endothelial cell migration through heterotrimeric G protein Gq/11-mediated activation of a small GTPase RhoA.
###end article-title 145
###begin article-title 146
The Cdc42 and Rac1 GTPases are required for capillary lumen formation in three-dimensional extracellular matrices.
###end article-title 146
###begin article-title 147
Temporal and spatial modulation of Rho GTPases during in vitro formation of capillary vascular network. Adherens junctions and myosin light chain as targets of Rac1 and RhoA.
###end article-title 147
###begin article-title 148
Rac regulates endothelial morphogenesis and capillary assembly.
###end article-title 148
###begin article-title 149
An integrin and Rho GTPase-dependent pinocytic vacuole mechanism controls capillary lumen formation in collagen and fibrin matrices.
###end article-title 149
###begin article-title 150
Molecular basis of endothelial cell morphogenesis in three-dimensional extracellular matrices.
###end article-title 150
###begin article-title 151
Rho activity critically and selectively regulates endothelial cell organization during angiogenesis.
###end article-title 151
###begin article-title 152
Cdc42- and Rac1-mediated endothelial lumen formation requires Pak2, Pak4 and Par3, and PKC-dependent signaling.
###end article-title 152
###begin article-title 153
###xml 101 106 <span type="species:ncbi:9606">human</span>
VEGF-A and alphaVbeta3 integrin synergistically rescue angiogenesis via N-Ras and PI3-K signaling in human microvascular endothelial cells.
###end article-title 153
###begin article-title 154
NSAIDs inhibit alpha V beta 3 integrin-mediated and Cdc42/Rac-dependent endothelial-cell spreading, migration and angiogenesis.
###end article-title 154
###begin article-title 155
Endothelial cell integrins and COX-2: mediators and therapeutic targets of tumor angiogenesis.
###end article-title 155
###begin article-title 156
Suppression of RhoG activity is mediated by a syndecan 4-synectin-RhoGDI1 complex and is reversed by PKCalpha in a Rac1 activation pathway.
###end article-title 156
###begin article-title 157
Syndecan-4-dependent Rac1 regulation determines directional migration in response to the extracellular matrix.
###end article-title 157
###begin article-title 158
Beta3-integrin regulates vascular endothelial growth factor-A-dependent permeability.
###end article-title 158
###begin article-title 159
CXCR4 chemokine receptor mediates prostate tumor cell adhesion through alpha5 and beta3 integrins.
###end article-title 159
###begin article-title 160
Regulation of the metastatic process by E-selectin and stress-activated protein kinase-2/p38.
###end article-title 160
###begin article-title 161
Integrating the VEGF signals leading to actin-based motility in vascular endothelial cells.
###end article-title 161
###begin article-title 162
alphavbeta3 integrin and angiogenesis: a moody integrin in a changing environment.
###end article-title 162
###begin article-title 163
Mechanisms and consequences of affinity modulation of integrin alpha(V)beta(3) detected with a novel patch-engineered monovalent ligand.
###end article-title 163
###begin article-title 164
Apoptosis of adherent cells by recruitment of caspase-8 to unligated integrins.
###end article-title 164
###begin article-title 165
Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors.
###end article-title 165
###begin article-title 166
###xml 25 29 <span type="species:ncbi:10090">mice</span>
Beta3-integrin-deficient mice are a model for Glanzmann thrombasthenia showing placental defects and reduced survival.
###end article-title 166
###begin article-title 167
###xml 89 104 <span type="species:ncbi:10090">transgenic mice</span>
Tie-1-directed expression of Cre recombinase in endothelial cells of embryoid bodies and transgenic mice.
###end article-title 167
###begin article-title 168
###xml 8 13 <span type="species:ncbi:10090">mouse</span>
Primary mouse endothelial cell culture for assays of angiogenesis.
###end article-title 168
###begin article-title 169
Cre-lox-regulated conditional RNA interference from transgenes.
###end article-title 169
###begin article-title 170
Alphavbeta3-integrin limits the contribution of neuropilin-1 to VEGF-induced angiogenesis.
###end article-title 170
###begin article-title 171
Cyclooxygenase-2 inhibition suppresses alphavbeta6 integrin-dependent oral squamous carcinoma invasion.
###end article-title 171
###begin article-title 172
###xml 31 35 <span type="species:ncbi:10090">mice</span>
Sponge-induced angiogenesis in mice and the pharmacological reactivity of the neovasculature quantitated by a fluorimetric method.
###end article-title 172
###begin article-title 173
VE-Cadherin-mediated cell-cell interaction suppresses sprouting via signaling to MLC2 phosphorylation.
###end article-title 173
###begin p 174
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 174
###begin p 175
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: This work was funded by Cancer Research UK, the Medical Research Council, Breast Cancer Campaign, The Association for International Cancer Research, and The Health Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
###end p 175

